0001171843-26-002094 | 10-K | XBRL Viewer

Fair Value Disclosures [Text Block]

NOTE 6 – FAIR VALUE MEASUREMENTS

The following table summarizes the Company’s fair value hierarchy for its assets measured at fair value on a recurring basis:

December 31, 2025	Fair Value		Level 1		Level 2		Level 3
Assets:
Digital assets	$	24,439,598	$	24,439,598	$	-	$	-
Embedded derivative related to digital asset receivable		77,893,482						77,893,482

December 31, 2024	Fair Value		Level 1		Level 2		Level 3
Assets:
Money market funds	$	300,000	$	300,000	$	-	$	-

The embedded derivative related to the digital asset receivable must be remeasured at fair value each reporting period in accordance with ASC 815, Derivatives and Hedging. Because there is no directly observable market for illiquid, contractually restricted ATH tokens subject to a time-based vesting schedule, the embedded derivative is classified as Level 3. The key unobservable input is the discount applied to reflect the lack of transferability and control during the restriction period. The discount is determined based on the remaining vesting period from each reporting period to the date on which the tokens become fully vested and available to claim, and is reduced ratably at each subsequent measurement date until it reaches zero at full vesting. As of December 31, 2025, applied discounts ranged from approximately 30% to 55%. Changes in fair value of the embedded derivative are recognized in the consolidated statements of net loss within "Gains (losses) on digital assets." There were no transfers into or out of Level 3 of the fair value hierarchy during the year ended December 31, 2025.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Note 14 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Compensation accruals	$ 99,684	$ 42,893
Accruals and reserves	172,188	191,804
Deferred revenue	35,819	80,005
Charitable contribution carryover	1,717	1,742
Unrealized loss on crypto assets	39,397,315	0
Intangibles	591,011	696,622
Capitalized R&D	711,632	1,016,330
Lease liabilities	387,395	551,917
Stock-based compensation	570,708	542,609
NOL and credits	27,010,332	24,479,583
Total deferred tax assets	68,977,801	27,603,505
Depreciation	(45,520)	(31,863)
Lease right-of-use assets	(369,859)	(513,256)
Total deferred tax liabilities	(415,379)	(545,119)
Net deferred tax assets	68,562,422	27,058,386
Less: valuation allowance	(68,562,422)	(27,058,386)
Total	$ 0	$ 0

Note 15 - Retirement Savings Plan

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Text Block]

NOTE 15 – RETIREMENT SAVINGS PLAN

The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. During 2025 and 2024, the Company matched 100% of the employee’s contribution up to 4.0% of their earnings. Employer contributions were $76,858 and $125,328 in 2025 and 2024, respectively, and are recorded within each of the captions comprising Operating expenses. There were no discretionary contributions to the plan in 2025 and 2024.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Note 14 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Income Taxes Paid [Table Text Block]

	Year Ended December 31,
	2025		2024
U.S. Federal	$	-	$	-
U.S. State		-		-
Foreign		-		-
Total income taxes paid (net of refunds)	$	-	$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended December 31,
	2025					2024
Tax computed at the statutory federal rate	$	(48,929,078	)	21.00	%		2,147,178		19.77	%
State income taxes, net of federal benefit (a)		-		0.00	%	$	-		0.00	%
Nontaxable or nondeductible items
Fair value of embedded derivatives		10,287,060		-4.42	%		-		0.00	%
Fair value of equity warrants		3,265,308		-1.40	%		-		0.00	%
Other nontaxable or nondeductible items		9,309		0.00	%		9,183		0.08	%
Other		124,835		-0.05	%		(13,898	)	-0.13	%
Change in valuation allowance		35,242,566		-15.13	%		(2,142,462	)	-19.73	%
Taxes at effective rate	$	-		0.00	%	$	-		0.00	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31, 2025			December 31, 2024
Deferred tax assets:
Compensation accruals	$	99,684		$	42,893
Accruals and reserves		172,188			191,804
Deferred revenue		35,819			80,005
Charitable contribution carryover		1,717			1,742
Unrealized loss on digital assets		39,397,315			-
Intangibles		591,011			696,622
Capitalized R&D		711,632			1,016,330
Lease liabilities		387,395			551,917
Stock-based compensation		570,708			542,609
NOL and credits		27,010,332			24,479,583
Total deferred tax assets		68,977,801			27,603,505

Deferred tax liabilities:
Depreciation		(45,520	)		(31,863	)
Lease right-of-use assets		(369,859	)		(513,256	)
Total deferred tax liabilities		(415,379	)		(545,119	)

Net deferred tax assets		68,562,422			27,058,386
Less: valuation allowance		(68,562,422	)		(27,058,386	)
Total	$	-		$	-

Note 12 - Stock-Based Compensation - Schedule of Share-based Compensation (Details)	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Outstanding, shares (in shares)	2,925
Share-Based Payment Arrangement, Option [Member]
Outstanding, shares (in shares)	3,101
Outstanding, average exercise price (in dollars per share) \| $ / shares	$ 1,240.5
Issued, shares (in shares)	0
Issued, average exercise price (in dollars per share) \| $ / shares	$ 0
Expired, shares (in shares)	(176)
Expired, average exercise price (in dollars per share) \| $ / shares	$ 20,729.18
Exercised, shares (in shares)	0
Exercised, average exercise price (in dollars per share) \| $ / shares	$ 0
Outstanding, shares (in shares)	2,925
Outstanding, average exercise price (in dollars per share) \| $ / shares	$ 1,334.07

Note 18 - Subsequent Events

12 Months Ended

Dec. 31, 2025

Subsequent Events [Text Block]

NOTE 18 – SUBSEQUENT EVENTS

Departure of DNA Director and Chief Investment Officer

On January 15, 2026, Shawn Matthews resigned as a director of the Company, effective as of January 15, 2026. On January 19, 2026, Thomas McLaughlin resigned as the Chief Investment Officer of the Company, effective as of January 19, 2026.

Departure of Chief Executive Officer

On February 6, 2026, the Board of Directors of Axe Compute Inc. voted to terminate, without cause, the employment of Raymond F. Vennare with the Company, effective as of February 9, 2026. In connection with his termination, Mr. Vennare entered into a separation agreement dated February 9, 2026 (the “Separation Agreement”), pursuant to which Mr. Vennare will receive certain separation benefits, contingent upon Mr. Vennare signing, delivering and not rescinding or revoking a general release of claims in favor of the Company. The Separation agreement provides for, among other things, (i) the payment of $575,000 in severance pay, which amount is equal to one year of Mr. Vennare’s base salary, (ii) a bonus for 2025 in the amount of $287,500, and (iii) a lump sum payment to assist with the cost of continued healthcare coverage. The foregoing description of the material terms of the Separation Agreement is not complete and is qualified in its entirety by reference to the full text thereof, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Appointment of Chief Executive Officer

In connection with Mr. Miglino’s appointment as Chief Executive Officer of the Company, the Company and Mr. Miglino entered into an employment agreement, dated February 9, 2026 (the “Employment Agreement”), which provides for, among other things, payment to Mr. Miglino of an annual base salary equal to $575,000, and at the discretion of the Board’s Compensation Committee (the “Committee”), to receive grants of stock options or other equity awards. Mr. Miglino will also be eligible to participate in the Company’s (i) bonus program with annual cash bonus equal up to 50% of his salary or at the discretion of the Committee, a higher percentage based on his and the Company’s performance, (ii) long-term incentive plan to be adopted and maintained by the Compensation Committee, and (iii) standard employee benefit plans generally available to executive employees of the Company.

In addition, as a material inducement to Mr. Miglino’s appointment as Chief Executive Officer, on February 9, 2026 (the “Grant Date”) the Company granted Mr. Miglino stock options (the “Options”) to purchase 500,000 shares of the Company’s common stock at an exercise price equal to the closing price of the Company’s common stock on the Grant Date, pursuant to a Stock Option Inducement Award Agreement (the “Option Agreement”) between Mr. Miglino and the Company. One-third of the Options will vest on the first anniversary of the Grant Date with the remaining two-thirds of the Options vesting in equal monthly installments over the following twenty-four months, in each case subject to Mr. Miglino’s continued employment with or service to the Company through each applicable vesting date.

Compute Contracts

In March 2026, the Company further executed on its strategic transition by executing contracts with several enterprise customers to provide access to remote GPU compute capacity on an hourly basis. The service periods of such contracts range in length from one month to approximately two years. In exchange for the services provided, the Company will collect various fees from customers, including monthly service fees, denominated in US dollars and payable in US dollars or stablecoins. The Company is in the process of analyzing the terms and conditions of such agreements to determine the appropriate accounting treatment under US GAAP, including application of ASC 606 to identify performance obligations, allocate the transaction price, and more. As a result, an estimate of the financial effect on the Company’s financial statements cannot be made at this time.

Note 1 - Organization

12 Months Ended

Dec. 31, 2025

Business Description and Basis of Presentation [Text Block]

NOTE 1 – ORGANIZATION

Nature of Operations

Axe Compute Inc. (“Axe Compute” or the “Company”) undertook a significant strategic shift in late 2025 when the Company adopted a digital asset treasury strategy (the “Treasury Strategy”) focused on the Aethir token (“ATH”), the native utility token of the Aethir network. Following the adoption of the Treasury Strategy, the Company began accumulating ATH in October 2025, and later in 2025, the Company expanded its business strategy to include a compute business under the Axe Compute brand, under which the Company seeks to provide customers with access to graphics processing unit (“GPU”) compute capacity for artificial intelligence (“AI”) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. Collectively, these activities are referred to as the Compute Services and Treasury Management operating segment. Consistent with the evolution of the Company’s business strategy, the Company was renamed from Predictive Oncology Inc. to Axe Compute Inc. on December 11, 2025.

Axe Compute also continues to operate its legacy oncology drug discovery solutions business designed to support the discovery and development of optimal cancer therapies. In the legacy business, the Company uses AI and its proprietary biobank of 150,000+ tumor samples, categorized by tumor type, to provide actionable insights about drug compounds to improve the drug discovery process and increase the probability of drug compound success. The Company also creates and develops tumor-specific 3D cell culture models mimicking the physiological environment of human tissue, enabling better-informed decision-making during drug development. In February 2026, the Company announced that it is exploring strategic alternatives for this oncology drug discovery solutions business, but the Company’s Board of Directors has not committed to a specific course of action. Accordingly, the oncology drug discovery solutions business did not meet the criteria under Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 205-20, Discontinued Operations to be classified as discontinued operations and held for sale, and therefore is reflected as continuing operations within these consolidated financial statements.

During the first quarter of 2025, the Company’s former Eagan operating segment, which produced the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal, met the criteria to be reported as discontinued operations. See Note 3 – Discontinued Operations for further discussion.

For further discussion of the Company’s operating segments as of and for the year ended December 31, 2025, see Note 17 – Segment Information for further discussion.

Aethir Treasury Strategy

On September 29, 2025, the Company announced the launch of its Treasury Strategy focused on ATH. Aethir is a leading decentralized physical infrastructure network developed by DCI Foundation, a Panama foundation company (“DCI”), that provides a decentralized graphics processing unit (“GPU”) network, connecting producers and consumers of GPU compute power at enterprise scale, supporting applications such as artificial intelligence computation, gaming and cloud workloads. ATH, the native token of the Aethir network, is a utility token used for GPU rentals, staking, validation and the provision of network rewards on the Aethir network. ATH functions as a proxy for a unit of GPU compute power and serves as a medium of exchange and unit of incentives for participants in the Aethir network. Participants in the Aethir network can generate yield or other rewards by staking or lending ATH or by otherwise serving as a source of ATH liquidity.

Pursuant to the Treasury Strategy, the Company intends to continue acquiring additional ATH in the open market and intends to earn yield on its ATH treasury holdings by engaging in ATH staking and other activities, though the Company had not yet commenced any staking activities as of December 31, 2025. As a holder of ATH, the Company accrues unrealized gains or losses from any appreciation or depreciation, as applicable, in the value of ATH tokens, which trade on various cryptocurrency exchanges.

The Company’s management is focusing its resources on the Treasury Strategy and a significant portion of the Company’s balance sheet will be allocated to holding ATH pursuant to its Treasury Strategy.

Currently, the Treasury Strategy is primarily dedicated to ATH, and the Company does not intend to accumulate other digital assets in the near term. As a result, the Company’s assets will be highly concentrated in a single digital asset. Adverse developments specific to ATH, its protocol, or its network could have a disproportionate impact on the Company’s financial condition and results of operations.

The Company’s Treasury Strategy is intended to bring value to its stockholders through the following:

●

utilizing proceeds from equity and debt financings to purchase and hold ATH;

●

staking the majority of the ATH in the Company’s treasury to earn a staking yield and turn the treasury into a productive asset;

●

purchasing ATH at a discount to the current spot price; and

●

selling the Company’s ATH holdings, whether on the open market, through block trades, or other negotiated transactions, for various reasons and at various times, including, in order to fund its working capital and general corporate needs.

Refer to the subheading “Risks and Uncertainties” below for further discussion regarding risks related to the Company’s Treasury Strategy.

Liquidity

Since the adoption of the Company’s Treasury Strategy, the Company has raised capital through private investment in public equity (“PIPE”) transactions and at-the-market (“ATM”) sales of shares of common stock. The Company has deployed the majority of the cash proceeds from these transactions to acquire ATH. Additional details regarding these equity offerings are included in Note 11 – Stockholders’ Equity. These capital raises have strengthened the Company’s liquidity position, and the $10.8 million of cash and cash equivalents remaining as of December 31, 2025, together with $24.4 million of digital assets, represent readily accessible sources of liquidity. The Company believes its sources of liquidity will be sufficient to allow the Company to fund its planned operations for at least the next twelve months from the date of this Annual Report on Form 10-K.

Reverse Stock Split

On September 19, 2025, the Company’s stockholders approved an amendment to the Company’s certificate of incorporation, as amended, to effect a one-for-fifteen reverse stock split of the Company’s common stock. On September 29, 2025, the Company completed a one-for-fifteen reverse stock split that was effective for trading purposes on September 30, 2025 (the “Reverse Stock Split”). All numbers of shares and per-share amounts in this report have been adjusted to reflect the Reverse Stock Split.

As a result of the Reverse Stock Split, every 15 shares of issued and outstanding common stock were combined into one issued and outstanding share of common stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split and any fractional shares that would otherwise have resulted from the Reverse Stock Split were rounded up to the nearest whole share. The Reverse Stock Split did not change the total number of authorized shares of common stock or preferred stock.

NASDAQ

On November 20, 2024, the Company was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”), because the Company’s stockholders’ equity of $1,966,969, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, was below the required minimum of $2.5 million. On June 9, 2025, the Company received a letter (the “Notice”) from the Staff of Nasdaq notifying the Company that because the Company had not regained compliance with the Stockholders’ Equity Requirement, the Staff had determined to delist the Company’s securities from The Nasdaq Capital Market. On June 11, 2025, the Company submitted a request for a hearing before Nasdaq’s Hearings Panel (the “Panel”), which stayed the suspension of the Company’s securities. A hearing before the Panel was held on July 17, 2025, where the Company presented plans for regaining and maintaining compliance with the continued listing standards and requested an exception from the continued listing standards through December 8, 2025, to provide the Company the ability to evidence compliance with the standards.

On July 8, 2025, the Company received a letter from the Staff indicating that the bid price for its common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued listing under Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notification had no immediate effect on the listing of the Company’s common stock.

On July 23, 2025, the Company was notified by Nasdaq that the Panel had granted the Company’s request for continued listing on The Nasdaq Capital Market pursuant to an extension through December 8, 2025, to demonstrate compliance with all continued listing requirements, including the Stockholders’ Equity Requirement and Minimum Bid Price Requirement.

On September 29, 2025, the Company completed the Reverse Stock Split, which was effective for trading purposes on September 30, 2025. As a result, the Company’s stock price increased significantly, and the Company regained compliance with the Minimum Bid Price Requirement as confirmed by the Staff via a letter dated October 14, 2025.

On December 1, 2025, the Company received formal notice from the Panel notifying the Company that it was in compliance with the Stockholders’ Equity Requirement. Accordingly, the previously disclosed listing matter has been closed. Nasdaq’s notice further stated that pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a mandatory panel monitor for a period of one year from December 1, 2025. If, within that one-year monitoring period, the Staff finds the Company again out of compliance with the Stockholders’ Equity Requirement, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Nasdaq Listing Rule 5810(c)(3). Instead, the Staff will issue a delist determination letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened hearings panel if the initial Panel is unavailable.

Note 8 - Leases - Lease Information (Details)	Dec. 31, 2025	Dec. 31, 2024
Weighted average remaining lease term – operating leases in years (Year)	2 years 1 month 28 days	3 years 1 month 28 days
Weighted average discount rate – operating leases	13.00%	13.00%

Note 16 - Loss Per Share (Details Textual)	Dec. 31, 2025 shares
Class of Warrant or Right, Outstanding (in shares)	1,623,179
Prefunded Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)	16,119,095

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted [Flag]	true

Note 17 - Segment Information - Segments (Details) - USD ($)		12 Months Ended
	Dec. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Revenue	$ 125,284	$ 125,284	$ 84,812
Assets, Excluding Discontinued Operations	52,888,346	52,888,346	3,508,778
Gains and (losses) from operations	(152,490,550)	(152,490,550)	0
Depreciation and amortization		129,038	132,336
Cost of revenues	72,622		78,285
Expenditures for additions to long-lived assets			3,032
General and administrative expenses	25,924,358	25,924,358	7,235,797
Research and development expenses	2,147,222		2,241,461
Sales and marketing expenses	406,247	406,247	833,199
Total operating (loss)	(180,915,715)	(180,915,715)	(10,303,930)
Other segment items	797,068		79,275
Net Income (Loss), Excluding Discontinued Operations	(232,853,647)		(10,224,655)
Gain (loss) on derivative instruments	(52,735,000)	(52,735,000)	1,376
Operating Segments [Member] \| Compute Services and Treasury Management Segment [Member]
Revenue	0		0
Assets, Excluding Discontinued Operations	49,455,174	49,455,174	0
Gains and (losses) from operations	(152,490,550)
Depreciation and amortization		0	0
Cost of revenues	0		0
Expenditures for additions to long-lived assets		0	0
General and administrative expenses	16,241,611		0
Research and development expenses	0		0
Sales and marketing expenses	0		0
Total operating (loss)	(168,732,161)		0
Other segment items	117,463		0
Net Income (Loss), Excluding Discontinued Operations	(221,349,698)		0
Gain (loss) on derivative instruments	(52,735,000)
Operating Segments [Member] \| Drug Discovery Services Segment [Member]
Revenue	125,284		84,812
Assets, Excluding Discontinued Operations	1,930,898	1,930,898	2,615,291
Gains and (losses) from operations	0
Depreciation and amortization		121,261	124,939
Cost of revenues	72,622		78,285
Expenditures for additions to long-lived assets		0	3,032
General and administrative expenses	1,726,908		2,022,732
Research and development expenses	2,137,042		2,234,501
Sales and marketing expenses	0		5
Total operating (loss)	(3,811,288)		(4,250,711)
Other segment items	676,702		(606)
Net Income (Loss), Excluding Discontinued Operations	(3,134,586)		(4,251,317)
Gain (loss) on derivative instruments	0
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Revenue	0		0
Assets, Excluding Discontinued Operations	1,502,274	1,502,274	893,487
Gains and (losses) from operations	0
Depreciation and amortization		7,777	7,397
Cost of revenues	0		0
Expenditures for additions to long-lived assets		$ 0	0
General and administrative expenses	7,955,839		5,213,065
Research and development expenses	10,180		6,960
Sales and marketing expenses	406,247		833,194
Total operating (loss)	(8,372,266)		(6,053,219)
Other segment items	2,903		79,881
Net Income (Loss), Excluding Discontinued Operations	(8,369,363)		$ (5,973,338)
Gain (loss) on derivative instruments	$ 0

Consolidated Statements of Cash Flows	12 Months Ended
Consolidated Statements of Cash Flows	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Cash flow from continuing operating activities:
Net loss	$ (233,095,203)	$ (12,664,388)
Less: loss from discontinued operations	(241,556)	(2,439,733)
Net loss from continuing operations	(232,853,647)	(10,224,655)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	129,038	132,337
Amortization of operating lease right-of-use assets	559,538	495,869
Write off of aged accounts payable and accrued expenses	(676,678)	0
Vesting expense	1,032,515	906
Shares of common stock issued to employees and nonemployees	15,550,146	99,253
(Gain) loss on derivative instruments	52,735,000	(1,376)
(Gain) loss on digital assets	152,490,550	0
Loss on disposal of property and equipment	0	803
Loss on disposal of intangible assets	0	4,738
Changes in assets and liabilities:
Accounts receivable	2,034	45,795
Prepaid expense and other assets	33,603	119,687
Accounts payable	1,005,900	(169,105)
Accrued expenses and other	751,132	(154,521)
Contract liabilities	(80,000)	(45,755)
Operating lease liability	(555,170)	(407,060)
Net cash used in continuing operating activities:	(9,876,039)	(10,103,084)
Cash flow from continuing investing activities:
Crypto assets purchased	(32,616,819)	0
Purchase of property and equipment	0	(9,510)
Net cash used in continuing investing activities:	(32,616,819)	(9,510)
Cash flow from continuing financing activities:
Proceeds from issuance of common stock and warrants	56,005,986	4,960,562
Costs to issue common stock and warrants	(4,048,995)	(870,960)
Proceeds from issuance of financing note payable	264,048	275,098
Repayment of note payable	(156,097)	(425,506)
Payments for taxes related to net share settlement of restricted stock units	(58,369)	0
Net cash provided by continuing financing activities	52,006,573	3,939,194
Discontinued operations:
Net cash used in operating activities	(82,538)	(1,852,587)
Net cash provided by investing activities	625,000	32,000
Net cash provided by (used in) financing activities	0	0
Net cash provided by (used in) discontinued operations	542,462	(1,820,587)
Net increase (decrease) in cash	10,056,177	(7,993,987)
Cash and cash equivalents from continuing operations at beginning of period	611,822	8,357,294
Cash and cash equivalents from discontinued operations at beginning of period	122,851	371,366
Less: Cash from discontinued operations at end of period	0	(122,851)
Cash and cash equivalents from continuing operations at end of period	10,790,850	611,822
Supplemental disclosure for cash flow information:
Cash payments for interest	8,960	11,466
Non-cash transactions:
Digital assets received pursuant to securities purchase agreements	62,973,982	0
Digital asset receivable received pursuant to securities purchase agreements	96,824,502	0
Vested ATH claimed from Locked ATH Receivable at Fair Value	3,445,865	0
Shares issued for vested restricted stock units, net of shares withheld for taxes	502	0
Equipment transferred from discontinued operations	0	5,140
Reverse Stock Split [Member]
Non-cash transactions:
Common stock issued in connection with reverse stock split	$ 727	$ 0

Fair value of vested ATH claimed from ATH Receivable.

+ References + Details

Note 2 - Summary of Significant Accounting Policies - Property Plant and Equipment Useful Life (Details)

Dec. 31, 2025

Minimum [Member]

4 years

Maximum [Member]

Office Equipment [Member] | Minimum [Member]

10 years

Office Equipment [Member] | Maximum [Member]

3 years

Leasehold Improvements [Member] | Minimum [Member]

10 years

Leasehold Improvements [Member] | Maximum [Member]

1 year

^[1]

2 years

^[1]

[1]	Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 7 - Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Table Text Block]

	As of December 31, 2025			As of December 31, 2024
Computers, software, and office equipment	$	170,350		$	170,350
Leasehold improvements		166,847			306,961
Laboratory equipment		1,692,230			1,692,230
Total		2,029,427			2,169,541
Less: Accumulated depreciation		(1,806,299	)		(1,821,953	)
Total Property and equipment, net	$	223,128		$	347,588

Note 12 - Stock-Based Compensation - Schedule of Listing of Stock Options (Details)	Dec. 31, 2025 $ / shares shares
Shares, options (in shares) \| shares	2,925
Minimum [Member]
Price, options (in dollars per share)	$ 93.3
Maximum [Member]
Price, options (in dollars per share)	$ 17,250
Stock Options 2016 [Member]
Shares, options (in shares) \| shares	25
Stock Options 2016 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 462
Stock Options 2016 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 12,750
Stock Options 2017 [Member]
Shares, options (in shares) \| shares	678
Stock Options 2017 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 462
Stock Options 2017 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 6,300
Stock Options 2018 [Member]
Shares, options (in shares) \| shares	205
Stock Options 2018 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 462
Stock Options 2018 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 3,390
Stock Options 2019 [Member]
Shares, options (in shares) \| shares	903
Stock Options 2019 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 462
Stock Options 2019 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 2,370
Stock Options 2020 [Member]
Shares, options (in shares) \| shares	1,002
Stock Options 2020 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 219.75
Stock Options 2020 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 492
Stock Options 2021 [Member]
Shares, options (in shares) \| shares	48
Stock Options 2021 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 375
Stock Options 2021 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 399
Stock Options 2022 [Member]
Shares, options (in shares) \| shares	48
Stock Options 2022 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 115.5
Stock Options 2022 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 219.75
Stock Options 2023 [Member]
Shares, options (in shares) \| shares	16
Stock Options 2023 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 93.3
Stock Options 2023 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 93.3
Stock Options 2024 [Member]
Shares, options (in shares) \| shares	0
Stock Options 2024 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0
Stock Options 2024 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 0
Stock Options 2025 [Member]
Shares, options (in shares) \| shares	0
Stock Options 2025 [Member] \| Minimum [Member]
Price, options (in dollars per share)	$ 0
Stock Options 2025 [Member] \| Maximum [Member]
Price, options (in dollars per share)	$ 0

Note 14 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note 14 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Income Tax Expense (Benefit)	$ 0	$ 0
Income Tax Limitations, Equity Issuance	435,000
Income Tax Limitation, Equity Issuance, Aggregate Total	4,600,000
Unrecognized Tax Benefits	0
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	110,759,174
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	14,857
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	110,744,317
Operating Loss Carryforwards, Valuation Allowance	55,645,772
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	57,161,699
Operating Loss Carryforwards, Valuation Allowance	$ 12,916,650

Note 6 - Fair Value Measurements (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net	$ 0
Aethir (ATH) [Member] \| Minimum [Member] \| Measurement Input, Discount Rate [Member]
Embedded Derivative Asset, Measurement Input	0.30
Aethir (ATH) [Member] \| Maximum [Member] \| Measurement Input, Discount Rate [Member]
Embedded Derivative Asset, Measurement Input	0.55

Note 12 - Stock-Based Compensation (Details Textual) - USD ($)				12 Months Ended
	Dec. 10, 2025	Oct. 07, 2025	Sep. 09, 2025	Dec. 31, 2025	Dec. 31, 2024
Stock Issued During Period, Value, Issued for Services				$ 100,000	$ 99,253
Share-Based Payment Arrangement, Expense				16,482,661	906
Strategic Advisor Warrants [Member]
Class of Warrant or Right, Grant Date Fair Value		$ 15,400,000
Warrants and Rights Outstanding, Term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,348,906
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 11.6265
Allocated Share Based Compensation, Warrants				$ 15,400,000	$ 15,400,000
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 731.25
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				3 years
Share-Based Payment Arrangement, Option [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)				10 years
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)			60,101
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 5,381
Restricted Stock Units (RSUs) [Member] \| Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)	20,000		8,331
Restricted Stock Units (RSUs) [Member] \| Chief Financial Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)			6,467
Restricted Stock Units (RSUs) [Member] \| Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)			25,872

Note 7 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Depreciation	$ 124,460	$ 127,354
Property, Plant and Equipment [Member]
Asset Impairment Charges	$ 0	$ 0

Note 16 - Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended December 31,
	2025			2024
Numerator:
Net (loss) from continuing operations	$	(232,853,647	)	$	(10,224,655	)
Net (loss) from discontinued operations		(241,556	)		(2,439,733	)
Net loss attributable to common stockholders	$	(233,095,203	)	$	(12,664,388	)

Denominator:
Weighted average common shares outstanding - basic		17,429,861			363,583
Dilutive effect of stock options, warrants and preferred stock (1)		-			-
Weighted average common shares outstanding - diluted		17,429,861			363,583

Net (loss) from continuing operations attributable to common stockholders per common share – basic and diluted	$	(13.36	)	$	(28.12	)
Net (loss) from discontinued operations attributable to common stockholders per common share – basic and diluted		(0.01	)		(6.71	)
(Loss) per common share - basic and diluted		(13.37	)		(34.83	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Year Ended December 31,
	2025		2024
Stock options		2,925		3,101
Stock warrants		1,623,179		183,411
Restricted stock units		20,000		-
Preferred stock: Series B		2		2

Note 17 - Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Year Ended December 31, 2025
	Compute Services and Treasury Management			Drug Discovery Services			Corporate			Total
Revenue	$	-		$	125,284		$	-		$	125,284
Gains and (losses) from operations		(152,490,550	)		-			-			(152,490,550	)
Cost of revenues		-			72,622			-			72,622
General and administrative expenses		16,241,611			1,726,908			7,955,839			25,924,358
Research and development expenses		-			2,137,042			10,180			2,147,222
Sales and marketing expenses		-			-			406,247			406,247
Total operating (loss)		(168,732,161	)		(3,811,288	)		(8,372,266	)		(180,915,715	)
Gain (loss) on derivative instruments		(52,735,000	)		-			-			(52,735,000	)
Other segment items		117,463			676,702			2,903			797,068
Segment loss	$	(221,349,698	)	$	(3,134,586	)	$	(8,369,363	)	$	(232,853,647	)

	December 31, 2025
	Compute Services and Treasury Management		Drug Discovery Services		Corporate		Total
Assets	$	49,455,174	$	1,930,898	$	1,502,274	$	52,888,346
Depreciation and amortization		-		121,261		7,777		129,038
Expenditures for additions to long-lived assets		-		-		-		-

	Year Ended December 31, 2024
	Compute Services and Treasury Management		Drug Discovery Services			Corporate			Total
Revenue	$	-	$	84,812		$	-		$	84,812
Cost of revenues		-		78,285			-			78,285
General and administrative expenses		-		2,022,732			5,213,065			7,235,797
Research and development expenses		-		2,234,501			6,960			2,241,461
Sales and marketing expenses		-		5			833,194			833,199
Total operating loss		-		(4,250,711	)		(6,053,219	)		(10,303,930	)
Other segment items		-		(606	)		79,881			79,275
Segment loss	$	-		(4,251,317	)	$	(5,973,338	)	$	(10,224,655	)

	December 31, 2024
	Compute Services and Treasury Management		Drug Discovery Services		Corporate		Total
Assets	$	-	$	2,615,291	$	893,487	$	3,508,778
Depreciation and amortization		-		124,939		7,397		132,336
Expenditures for additions to long-lived assets		-		3,032		-		3,032

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2025	Mar. 27, 2026	Jun. 30, 2025
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2025
Document Transition Report	false
Entity File Number	001-36790
Entity Registrant Name	Axe Compute Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1007393
Entity Address, Address Line One	91 43rd Street, Suite 110
Entity Address, City or Town	Pittsburgh
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	15201
City Area Code	412
Local Phone Number	432-1500
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	AGPU
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 7,965,485
Entity Common Stock, Shares Outstanding (in shares)		5,539,267
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	Pittsburgh, Pennsylvania
Entity Central Index Key	0001446159
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Statement of Stockholders' Equity - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Registered Direct Offering [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Renovaro Extension Agreement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] At The Market Offering [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] May 2025 Private Placement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Yorkville SEPA [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] August 2025 Private Placement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] October 2025 Private Placement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member] Sales Agreement [Member]	Common Stock [Member] Registered Direct Offering [Member]	Common Stock [Member] Renovaro Extension Agreement [Member]	Common Stock [Member] At The Market Offering [Member]	Common Stock [Member] May 2025 Private Placement [Member]	Common Stock [Member] Yorkville SEPA [Member]	Common Stock [Member] August 2025 Private Placement [Member]	Common Stock [Member] October 2025 Private Placement [Member]	Common Stock [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Sales Agreement [Member]	Additional Paid-in Capital [Member] Registered Direct Offering [Member]	Additional Paid-in Capital [Member] Renovaro Extension Agreement [Member]	Additional Paid-in Capital [Member] At The Market Offering [Member]	Additional Paid-in Capital [Member] May 2025 Private Placement [Member]	Additional Paid-in Capital [Member] Yorkville SEPA [Member]	Additional Paid-in Capital [Member] August 2025 Private Placement [Member]	Additional Paid-in Capital [Member] October 2025 Private Placement [Member]	Additional Paid-in Capital [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Sales Agreement [Member]	Retained Earnings [Member] Registered Direct Offering [Member]	Retained Earnings [Member] Renovaro Extension Agreement [Member]	Retained Earnings [Member] At The Market Offering [Member]	Retained Earnings [Member] May 2025 Private Placement [Member]	Retained Earnings [Member] Yorkville SEPA [Member]	Retained Earnings [Member] August 2025 Private Placement [Member]	Retained Earnings [Member] October 2025 Private Placement [Member]	Retained Earnings [Member] The February 2021, June 2021, and May 2022 Warrants [Member]	Retained Earnings [Member]	Sales Agreement [Member]	Registered Direct Offering [Member]	Renovaro Extension Agreement [Member]	At The Market Offering [Member]	May 2025 Private Placement [Member]	Yorkville SEPA [Member]	August 2025 Private Placement [Member]	October 2025 Private Placement [Member]	The February 2021, June 2021, and May 2022 Warrants [Member]	Total
Balance (in shares) at Dec. 31, 2023								79,246										270,863
Balance at Dec. 31, 2023								$ 792										$ 2,709										$ 176,030,162										$ (167,761,883)										$ 8,271,780
Issuance of shares to non-employees (in shares)																		2,597
Issuance of shares to non-employees																		$ 26										99,227										0										99,253
Issuance of shares pursuant to At-The-Market financing, net of issuance costs (in shares)									107,140
Issuance of shares pursuant to At-The-Market financing, net of issuance costs									$ 1,071										$ 3,120,931										$ 0										$ 3,122,002
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs (in shares)																	63,875
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs																	$ 639										$ 966,961										$ 0										$ 967,600
Stock-based compensation, net of forfeitures																												1,143																				1,143
Net loss																												0										(12,664,388)										(12,664,388)
Balance (in shares) at Dec. 31, 2024								79,246										444,475
Balance at Dec. 31, 2024								$ 792										$ 4,445										180,218,424										(180,426,271)										(202,610)
Issuance of shares to non-employees (in shares)								0										6,667
Issuance of shares to non-employees								$ 0										$ 67										99,933										0										100,000
Issuance of shares pursuant to At-The-Market financing, net of issuance costs (in shares)	0	0	0	0	0	0				24,223	31,153	139,680	18,692	8,033	36,237																								139,680
Issuance of shares pursuant to At-The-Market financing, net of issuance costs	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0				$ 242	$ 312	$ 1,397	$ 187	$ 80	$ 362					$ 465,063	$ 499,688	$ 1,528,826	$ 299,813	$ 99,920	$ 412,731					$ 0	$ 0	$ 0	$ 0	$ 0	$ 0					$ 465,305	$ 500,000	$ 1,530,223	$ 300,000	$ 100,000	$ 413,093
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs (in shares)								0										739,508
Issuance of shares pursuant to Warrant Inducement Transaction, net of issuance costs								$ 0										$ 7,395										1,598,532										0										1,605,927
Stock-based compensation, net of forfeitures																												1,032,515																				1,032,515
Net loss																		$ 0										0										(233,095,203)										(233,095,203)
Round up of fractional shares pursuant to reverse stock split (in shares)								0										72,745
Round up of fractional shares pursuant to reverse stock split								$ 0										$ 727																				0										0
Round up of fractional shares pursuant to reverse stock split																												(727)
Issuance of shares							$ 0									$ 25,116										$ 259,650,812										$ 0										$ 259,675,928
Issuance of shares (in shares)																2,511,552
Issuance of warrants to DNA Holdings Venture pursuant to Strategic Advisor Agreement																												15,350,146										0										15,350,146
Issuance of common stock in connection with restricted stock units vesting								$ 0										$ 502										(58,871)										0										(58,369)
Issuance of common stock in connection with restricted stock units vesting (in shares)																		50,208
Balance (in shares) at Dec. 31, 2025								79,246										4,083,173
Balance at Dec. 31, 2025								$ 792										$ 40,832										$ 461,196,805										$ (413,521,474)										$ 47,716,955

Note 6 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

December 31, 2025	Fair Value		Level 1		Level 2		Level 3
Assets:
Digital assets	$	24,439,598	$	24,439,598	$	-	$	-
Embedded derivative related to digital asset receivable		77,893,482						77,893,482

December 31, 2024	Fair Value		Level 1		Level 2		Level 3
Assets:
Money market funds	$	300,000	$	300,000	$	-	$	-

Cybersecurity Risk Management and Strategy Disclosure

12 Months Ended

Dec. 31, 2025

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

Risk Management and Strategy

As one of the critical elements of our overall ERM approach, our cybersecurity program is focused on the following key areas:

●

Governance. As discussed in more detail under the heading “Governance,” the Board maintains an active role concerning cybersecurity risk management including oversight of the Company’s employee personnel with extensive experience in the field.

●

Technical Safeguards and Risk Management Processes. We have implemented a risk management framework to identify, evaluate, and address cybersecurity risks. This framework includes the deployment of tools to detect potential threats, the maintenance of detailed incident logs, and the development of risk mitigation strategies. Our cybersecurity measures and policies are subject to regular testing and continuous improvement to adapt to new threats as they arise.

●

Education and Incident Reporting. We have instituted a company-wide security awareness training program to educate employees about cybersecurity risks and their role in maintaining our security posture. Continuous education and testing support our workforce in remaining knowledgeable and vigilant to cybersecurity threats. Employees are instructed to report all cybersecurity concerns directly to our internal information technology (“IT”) team for immediate assessment and response.

●

Cybersecurity Incident Response Plan. We maintain a comprehensive incident response plan designed to mitigate the impact of a cybersecurity incident. This plan includes protocols for internal response, external communication, and remediation efforts to minimize the impact on our operations and stakeholders.

●

Third-Party Risk Management. We maintain a risk-based approach to identifying and overseeing cybersecurity risks presented by third parties, including vendors, service providers and other external users of our systems, as well as the systems of third parties that could adversely impact our business in the event of a cybersecurity incident affecting those third-party systems.

We engage in the periodic assessment and testing of our policies, standards, processes, and practices that are designed to address cybersecurity threats and incidents. These efforts include a range of activities, including audits, assessments, vulnerability testing, and other exercises focused on evaluating the effectiveness of our cybersecurity measures and planning. We engage third parties to perform assessments on our cybersecurity measures, including information security maturity assessments, audits, and independent reviews of our information security control environment and operating effectiveness. The results of such assessments, audits, and reviews are reported to the Board, and we adjust our cybersecurity policies, standards, processes, and practices as necessary based on the information provided by these assessments, audits, and reviews.

Cybersecurity Risk Management Processes Integrated [Flag]

true

Cybersecurity Risk Management Processes Integrated [Text Block]

As one of the critical elements of our overall ERM approach, our cybersecurity program is focused on the following key areas:

Cybersecurity Risk Management Third Party Engaged [Flag]

true

Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]

true

Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]

false

Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]

We face a number of cybersecurity risks in connection with our business. Such risks have not materially affected us, including our business strategy, results of operations or financial condition, to date. For more information about the cybersecurity risks we face, see the risk factor entitled “Security breaches, loss of data, and other disruptions to our business or the business of our third-party service providers could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and reputation.” in Item 1A. Risk Factors.

Cybersecurity Risk Board of Directors Oversight [Text Block]

Governance

The Board oversees the Company’s ERM process, including the management of risks arising from cybersecurity threats. The Board receives reports on cybersecurity risks, which address a wide range of topics including recent developments, evolving standards, vulnerability assessments, third-party and independent reviews, the threat environment, technological trends, and information security considerations arising with respect to the Company’s peers and third parties. The Board also receives prompt and timely information regarding any cybersecurity incident that meets established reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed.

The Senior Director of IT and Cybersecurity, in coordination with our executive officers, work collaboratively across the Company to implement a program designed to protect the Company’s information systems from cybersecurity threats and to promptly respond to any cybersecurity incidents in accordance with the Company’s incident response plan. To facilitate the Company’s cybersecurity risk management program, the Company’s internal IT team is deployed to work with business functions across the Company to address cybersecurity threats and to respond to cybersecurity incidents. The Senior Director of IT and Cybersecurity, as leader of the internal IT team, monitors the prevention, detection, mitigation, and remediation of cybersecurity threats and incidents in real time, and reports such threats and incidents to the executive officers and Board when appropriate.

The Senior Director of IT and Cybersecurity has served in various roles in information technology and information security for more than two decades with a track record of managing systems compliant with relevant security standards. The Senior Director of IT and Cybersecurity has industry experience and education aligned with the Company’s work and the data we maintain. The Senior Director of IT and Cybersecurity’s expertise is complemented by that of the Company’s CEO and CFO, each with degrees in their respective fields and extensive leadership experience including experience managing risks at similar companies.

Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]

Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]

Cybersecurity Risk Role of Management [Text Block]

Cybersecurity Risk Management Positions or Committees Responsible [Flag]

true

Cybersecurity Risk Management Positions or Committees Responsible [Text Block]

Cybersecurity Risk Management Expertise of Management Responsible [Text Block]

Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]

Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]

true

Note 5 - Crypto Asset Holdings - Crypto Asset, Holding (Details) - Aethir (ATH) [Member]	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Units Held	2,837,163,868
Cost Basis	$ 101,258,178
Fair Value	$ 24,439,334	$ 0

Note 13 - Related Parties

12 Months Ended

Dec. 31, 2025

NOTE 13 – RELATED PARTIES

Agreements with DNA Holdings Venture, Inc. and its Representatives

In connection with the Company’s Treasury Strategy, and the Cash and Crypto PIPEs closed October 7, 2025, Shawn Matthews was appointed to the Company’s Board of Directors. Mr. Matthews served as Chief Executive Officer of DNA, at the time of his appointment to the Company’s Board of Directors. Additionally, the Company engaged Thomas McLaughlin, who at the time served as Chief Investment Officer of DNA, to serve as the Company’s Chief Investment Officer.

In connection with the Treasury Strategy, on October 7, 2025, the Company entered into the Strategic Advisor Agreement under which it engaged DNA as a strategic advisor to provide financial advisory services related to digital asset strategies and business development initiatives. As compensation for DNA’s services, the Company issued the Strategic Advisor Warrants with a five-year term to DNA to purchase up to 1,348,906 shares of its common stock at an exercise price of $11.6265 per share. The Strategic Advisor Warrants had a grant date fair value of $15.4 million.

The Company further engaged DNA under the Asset Management Agreement with a 10-year term, pursuant to which DNA will act as the Company’s asset manager with respect to its digital assets. As compensation for its services under the Asset Management Agreement, DNA is entitled to a 1.00% per annum asset-based management fee, plus an incentive fee equal to 25% of profits earned on managed assets over 7%. Total fees paid to DNA under the Asset Management Agreement were $722,390 during the year ended December 31, 2025.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Basis of Accounting, Policy [Policy Text Block]

Note 8 - Leases - Rent Obligation (Details)	Dec. 31, 2025 USD ($)
2026	$ 803,724
2027	827,909
2028	139,022
Total lease payments	1,770,655
Less: interest	(212,417)
Present value of lease liabilities	$ 1,558,238

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

The Company has prepared the consolidated financial statements in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (“SEC”) for consolidated financial statements. Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassified amounts had no impact on the Company’s previously reported financial position or results of operations.

The Company had two wholly owned subsidiaries, Helomics Corporation and Skyline Medical Inc. (“Skyline Medical”), as of and for the years ended December 31, 2025 and 2024. Skyline Medical remained a wholly owned subsidiary of Axe Compute following the March 14, 2025 asset purchase agreement between the Company and DeRoyal Industries, Inc., but the subsidiary’s ongoing activities are limited to wind down activities which were substantially completed as of December 31, 2025. The consolidated financial statements include the accounts of the Company and these wholly owned subsidiaries after elimination of intercompany transactions and balances as of and for the years ended December 31, 2025 and 2024.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Estimates are used in the following areas, among others: stock-based compensation expense, fair value of derivatives including embedded derivatives, fair value of digital assets, fair value of long-lived assets for impairment analyses, the valuation allowance included in the deferred income tax calculation, and accrued expenses.

Discontinued Operations, Policy [Policy Text Block]

Discontinued Operations

The Company disposed of its former Eagan and Birmingham operating segments during the years ended December 31, 2025, and 2024, respectively. Disposal groups that meet the discontinued operations criteria provided in the FASB ASC 205-20-45 are classified as discontinued operations. Assets and liabilities of discontinued operations are presented separately in the Company’s consolidated balance sheets and results of discontinued operations are reported as a separate component of net loss in the Company’s consolidated statements of net loss for all periods presented, resulting in changes to the presentation of certain prior period amounts. Results of discontinued operations are excluded from segment results for all periods presented. Cash flows from discontinued operations are also reported separately in the Company’s consolidated statements of cash flows.

Refer to Note 3 – Discontinued Operations for additional discussion of discontinued operations. All other notes to these consolidated financial statements present the results of continuing operations and exclude amounts related to discontinued operations for all periods presented.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

The Company considers all highly liquid instruments with maturities when purchased of three months or less to be cash equivalents. The Company places its cash with high quality financial institutions and believes its risk of loss is limited to amounts in excess of that which is insured by the Federal Deposit Insurance Corporation.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

As outlined in ASC 820, Fair Value Measurement, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC 820 establishes a three-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data in making fair value measurements, when available. Fair value measurements are classified according to the lowest level input that is significant to the valuation.

The fair value measurements of the Company’s derivatives were determined based on Level 3 inputs. The Company uses the Monte Carlo method and other acceptable valuation methodologies when valuing embedded features classified as derivatives on a recurring basis. See Note 5 – Digital Assets and Note 6 – Fair Value Measurements.

Receivable [Policy Text Block]

Receivables

Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts.

Amounts recorded in accounts receivable on the consolidated balance sheets include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance is maintained to provide for the estimated amount of receivables that will not be collected. The Company determines the allowance based on historical experience as well as external business factors expected to impact collectability such as economic factors. The Company reviews customers’ credit history before extending unsecured credit and establishes an allowance based upon factors surrounding the credit risk of specific customers, historical trends, and other information. Invoices are generally due 30 days after presentation. Accounts receivable over 30 days is generally considered past due. The Company does not accrue interest on past due accounts receivables. Receivables are written off once all collection attempts have failed and are based on individual credit evaluation and specific circumstances of the customer.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company maintains its cash and cash equivalent balances with high quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds.

Digital Assets [Policy Text Block]

Digital Assets

The Company’s digital assets primarily include holdings of ATH, which are measured at fair value in accordance with ASC 350-60, Intangibles – Goodwill and Other, Crypto Assets.

The Company reflects digital assets held at fair value on the consolidated balance sheets within the line item “Digital assets.” Changes in the fair value of digital assets are recognized in the consolidated statements of net loss within “Gains (losses) on digital assets.”

Purchases and sales of ATH are reflected as cash flows from investing activities in the consolidated statements of cash flows. Contributions of ATH received in connection with the equity offering transactions are presented as non-cash financing activities in the consolidated statements of cash flows. Contributions of ATH received from DCI are presented within adjustments to reconcile net loss to net cash used in operating activities in the consolidated statements of cash flows.

Refer to Note 5 – Digital Assets for additional information.

Digital Asset Receivable [Policy Text Block]

Digital Asset Receivable

Digital asset receivable represents the Company’s contractual right to receive ATH tokens in the future upon satisfaction of time-based vesting conditions. Because the Company does not control the underlying ATH tokens prior to vesting and claim, the locked ATH tokens are accounted for as a receivable rather than as a digital asset.

On the consolidated balance sheet, the host receivable component is presented as “Digital asset receivable.” The fair value of tokens that unlock within twelve months from December 31, 2025 is classified as a current asset, while the fair value of the remainder of locked tokens is classified as a noncurrent asset.

The embedded derivative associated with the digital asset receivable, reflecting the changes in fair value of the ATH to be received, is presented within the same line item as the host receivable and is measured at fair value at each reporting date. Changes in the fair value of the embedded derivative are recognized in the consolidated statements of net loss within “Gains (losses) on digital assets.”

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computers, software, and office equipment		3	-	10
Leasehold improvements (1)		1	-	2
Laboratory equipment		4	-	10

(1)

Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Upon retirement or sale of property and equipment, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-lived Assets

The Company reviews long-lived assets for impairment in accordance with ASC 360, Property, Plant and Equipment, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

The recoverability of an asset to be held and used is determined by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated undiscounted future cash flows, the Company records an impairment charge in the amount by which the carrying amount of the asset exceeds its fair value, which is determined by either a quoted market price, if any, or a value determined utilizing discounted cash flow techniques.

Lessee, Leases [Policy Text Block]

Leases

At inception of a contract a determination is made whether an arrangement meets the definition of a lease. A contract contains a lease if there is an identified asset, and the Company has the right to control the asset. Operating leases are recorded as right-of-use (“ROU”) assets with corresponding current and noncurrent operating lease liabilities on our consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 months or less at the commencement date are not recognized on the consolidated balance sheet and are expensed as incurred.

The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Variable lease payments generally represent the Company’s share of the landlord’s expenses and are recorded when incurred. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company recognizes revenue in accordance with the five-step process outlined in ASC 606, Revenue from Contracts with Customers (“ASC 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amount to the governmental authorities. Sales taxes are excluded from revenue and expenses. Advertising costs incurred in the Company’s efforts to obtain new customers are expensed as incurred.

Revenues from Services

The Company generates revenues from Contract Research Organization (“CRO”) services related to the development of 3D tumor-specific in vitro models for oncology drug discovery and research. The organ-specific disease models provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response.

The specific pattern of revenue recognition for CRO services is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company may execute a master service agreement with a customer that provides terms and conditions for the relationship between the Company and the customer. Detailed Statements of Work (SOWs) are then prepared to outline the specific services to be provided. The SOW and master service agreement, if applicable, form the contract with the customer under ASC 606. The Company evaluates each product or service promised in a contract to determine whether it represents a distinct performance obligation. Determining whether services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment. Contracts for CRO services generally contain one performance obligation to perform research and deliver appropriate data or reporting. The Company typically requires partial payment for CRO services prior to performance of the research service with the remainder of the transaction price due 30 days after delivery of data or reporting. Revenues from CRO services are generally recognized at the point in time when data and reports are provided to customers.

Contract Balances

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Advance payments received in excess of revenues recognized are classified as contract liabilities until such time as the revenue recognition criteria have been met.

Practical Expedients

The Company has elected not to determine whether contracts with customers contain significant financing components as contracts are generally for less than one year. The Company immediately expenses contract costs that would otherwise be capitalized and amortized over a period of less than one year. The Company recognizes shipping and handling costs at point of sale.

Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

The Company accounts for stock-based compensation expense in accordance with ASC 718, Compensation—Stock Compensation, which requires the Company to measure and recognize compensation expense in the financial statements based on the fair value at the date of grant for stock-based awards. The Company recognizes compensation expense for service-based equity-classified awards over their requisite service period and adjusts for forfeitures as they occur.

ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model which requires the input of significant assumptions including an estimate of the average period of time employees and directors will retain vested stock options before exercising them, the estimated volatility of the Company’s common stock price over the expected term, and the risk-free interest rate.

When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason, the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period that investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company’s common stock price over the expected term, and the risk-free interest rate. In the case of options granted to employees, the Company estimates the life to be the legal term.

Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognizes that. The Company’s common stock has been traded on the NASDAQ Capital Market exchange since 2015 and the Company has experienced significant volatility in its stock price. The assumptions used in calculating the fair value of stock-based payment awards represent the Company’s best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, its stock-based compensation expense could be materially different in the future.

The Company has a sequencing policy under ASC 815-40-35 that will apply if reclassification of contracts from equity to liabilities is necessary. If the Company is unable to demonstrate it has sufficient authorized shares, shares will be allocated based on the earliest issuance date of potentially dilutive financial instruments, with the earliest financial instruments receiving the first allocation of shares. Pursuant to ASC 815, stock-based awards issued to the Company’s employees are not subject to the sequencing policy.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Research and development costs are charged to operations as incurred. These costs include employee compensation costs, facilities and overhead, cloud computing costs, and other expenses incurred related to the pursuit of new products and services or enhancements to existing products and services.

Income Tax, Policy [Policy Text Block]

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

Under Internal Revenue Code Section 382, certain stock transactions that significantly change ownership could limit the amount of net operating carryforwards that may be utilized on an annual basis to offset taxable income in future periods. Consequently, the Company performed a Section 382 analysis as of December 31, 2025, which resulted in the limitation and expiration of a substantial portion of the Company’s loss carryforwards. In addition, the current net operating loss (“NOL”) carryforwards might be further limited by future issuances of our common stock. See Note 14 – Income Taxes.

Tax years after 2005 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Earnings Per Share, Policy [Policy Text Block]

Loss per Share

Basic loss per share is calculated using the weighted average number of shares outstanding during the year. Pre-funded warrants are included in the computation of earnings per share because the exercise price of the pre-funded warrants is nominal and there are no conditions that must be satisfied prior to their exercise. Diluted loss per share reflects the potential dilution of common share equivalents, such as outstanding options and warrants, in the weighted average number of common shares outstanding during the period, if dilutive. The diluted loss per share calculation excludes any potential conversion of options and warrants that would be anti-dilutive.

Risk and Uncertainties [Policy Text Block]

Risks and Uncertainties

The Company is subject to various risks including market risk, liquidity risk and other risks related to its concentration in ATH.

The price of ATH has been, and will likely continue to be, highly volatile. Our financial results and the market price of our common stock could be materially adversely affected if the price of ATH decreases substantially, as it has in the past, including as a result of shifts in market sentiment, speculative trading, macroeconomic trends, technology-related disruptions and regulatory announcements.

The Company holds its digital assets with a custodian that safeguards the Company’s private keys. The Company’s digital assets are controllable only by the possessor of both the unique public key and private key(s). The custodial services contracts do not restrict the Company’s ability to reallocate its digital assets among custodians. The Company’s ability to access, transfer, or withdraw its digital assets is therefore not contractually restricted, and the Company is able to convert or reallocate digital assets as needed to meet operating requirements or settle obligations. Cybersecurity threats, including hacking, phishing and other malicious attacks, could result in the loss, theft or misappropriation of our digital assets. If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain access to our private keys, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose some or all of our digital assets and our financial condition and results of operations could be materially adversely affected.

The Company also remains subject to risks associated with the biopharmaceutical industry. Risks include, but are not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the Food and Drug Administration, Clinical Laboratory Improvement Amendments, and other governmental agencies.

The Company is also subject to general economic and geopolitical uncertainties caused by inflation, rising interest rates, supply chain disruptions, tight labor markets, wage inflation, pricing volatility for certain goods and services, banking and financial sector disruptions, instability and volatility in the global markets, disruptions from a global pandemic, and geopolitical conflict. The impacts of economic and other global events could have a material adverse effect on our business, results of operations, liquidity or financial condition and heighten or exacerbate risks related to the Company.

The Company has evaluated all its activities and concluded that no other subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements, except as described above and in Note 18 – Subsequent Events.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the FASB. Recently issued ASUs not listed below either were assessed and determined to be not applicable or are currently expected to have no impact on the consolidated financial statements of the Company.

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU requires more detailed disclosures related to certain costs and expenses. The guidance requires entities to disclose amounts of certain expense categories included in expense captions presented on the face of the income statement, including purchases of inventory, employee compensation, depreciation, and intangible asset amortization. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The disclosure requirements may be applied either prospectively or retrospectively. Management is currently evaluating this ASU to determine its impact on the Company’s disclosures.

Recently Adopted Accounting Standards

Effective January 1, 2025, the Company adopted ASU 2023-08, Accounting for and Disclosure of Crypto Assets, which requires certain crypto assets that meet the scope criteria of ASC 350-60 to be measured at fair value, with changes recognized in net income each reporting period. Upon adoption, the Company began presenting in-scope digital assets separately from other intangible assets on the Consolidated Balance Sheets and recognizing unrealized gains and losses from remeasurement within “Gains (losses) on digital assets” in the Consolidated Statements of Net Loss. The Company also provides enhanced disclosures regarding the nature and amount of digital assets held, including the name of each significant digital asset, units held, cost basis, fair value, and the fair value of any digital assets subject to contractual sale restrictions. The adoption of ASU 2023-08 did not result in a cumulative-effect adjustment to opening retained earnings due to the commencement of the Company’s ATH Treasury Strategy in September 2025.

Effective January 1, 2025, the Company adopted ASU 2023-09, Improvements to Income Tax Disclosures, which requires expanded disaggregation of income tax information to enhance transparency and comparability. As a result, the Company now presents a more detailed reconciliation of the U.S. federal statutory income tax rate to the Company’s effective tax rate, including separate disclosure of state and local income taxes, foreign tax effects, tax credits, valuation allowance changes, nondeductible items, and changes in unrecognized tax benefits. The Company also discloses income taxes paid (net of refunds) disaggregated by federal, state, and significant foreign jurisdictions, including any individual jurisdiction that represents 5% or more of total income taxes paid. In addition, the Company now presents pretax income (loss) and income tax expense (benefit) disaggregated between domestic and foreign operations, with separate disclosure for any significant individual foreign jurisdictions. The Company adopted ASU 2023-09 on a retrospective basis.

Note 5 - Digital Assets - Reconciliation of Digital Assets (Details) - Aethir (ATH) [Member]	12 Months Ended
	Dec. 31, 2025 USD ($)
Fair Value, January 1, 2025	$ 0
Unlocked ATH received from investors	62,973,982
ATH contributed by DCI pursuant to Side Letter	2,230,949
ATH claimed from digital asset receivable	3,445,865
Purchases of ATH	32,607,382
Disposals	0
Crypto Asset, Unrealized Gain (Loss), Operating	(76,818,844)
Fair Value, December 31, 2025	$ 24,439,334

Note 4 - Contracts With Customers

12 Months Ended

Dec. 31, 2025

Collaborative Arrangement Disclosure [Text Block]

NOTE 4 – CONTRACTS WITH CUSTOMERS

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of December 31, 2025, and 2024, accounts receivable totaled $32,120 and $34,154, respectively. The allowance for accounts receivable balance was $0 as of both December 31, 2025, and 2024.

Advance payments received in excess of revenues recognized are classified as contract liabilities until such time as the revenue recognition criteria have been met. The Company’s contract liabilities, related primarily to development of 3D models, were $144,076 and $224,076 as of December 31, 2025, and 2024, respectively. During the year ended December 31, 2025, the Company recognized revenue of $80,000 from contract liabilities recorded as of December 31, 2024, primarily related to deposits for development of 3D models. The Company’s contract liabilities as of December 31, 2025, represent its remaining performance obligations.

Note 16 - Loss Per Share - Schedule of Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares) (in shares)	2,925	3,101
Warrant [Member]
Antidilutive Securities (in shares) (in shares)	1,623,179	183,411
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares) (in shares)	20,000	0
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares) (in shares)	2	2

Note 7 - Property and Equipment, Net

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment Disclosure [Text Block]

NOTE 7 – PROPERTY AND EQUIPMENT, NET

The Company’s property and equipment, net consisted of the following:

	As of December 31, 2025			As of December 31, 2024
Computers, software, and office equipment	$	170,350		$	170,350
Leasehold improvements		166,847			306,961
Laboratory equipment		1,692,230			1,692,230
Total		2,029,427			2,169,541
Less: Accumulated depreciation		(1,806,299	)		(1,821,953	)
Total Property and equipment, net	$	223,128		$	347,588

Depreciation expense, recorded within general and administrative expenses of continuing operations, was $124,460 and $127,354 for the years ended December 31, 2025, and 2024, respectively.

No impairment charges related to property and equipment held and used in continuing operations were incurred during the years ended December 31, 2025, and 2024.

Note 16 - Loss Per Share

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Text Block]

NOTE 16 – LOSS PER SHARE

The Company calculates basic loss per share based upon the weighted average number of common shares outstanding during the period, while the calculation of diluted earnings per share includes the dilutive effect of potential common shares outstanding during the period. The calculation of diluted earnings per share excludes all potential common shares, with the exception of pre-funded warrants, if their inclusion would have an anti-dilutive effect. A total of 16,119,095 pre-funded warrants are included in the computation of earnings per share because the exercise price of the pre-funded warrants is nominal and there are no conditions that must be satisfied prior to their exercise.

The following table presents the shares used in the basic and diluted loss per common share computations:

	Year Ended December 31,
	2025			2024
Numerator:
Net (loss) from continuing operations	$	(232,853,647	)	$	(10,224,655	)
Net (loss) from discontinued operations		(241,556	)		(2,439,733	)
Net loss attributable to common stockholders	$	(233,095,203	)	$	(12,664,388	)

Denominator:
Weighted average common shares outstanding - basic		17,429,861			363,583
Dilutive effect of stock options, warrants and preferred stock (1)		-			-
Weighted average common shares outstanding - diluted		17,429,861			363,583

Net (loss) from continuing operations attributable to common stockholders per common share – basic and diluted	$	(13.36	)	$	(28.12	)
Net (loss) from discontinued operations attributable to common stockholders per common share – basic and diluted		(0.01	)		(6.71	)
(Loss) per common share - basic and diluted		(13.37	)		(34.83	)

(1)

The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive:

	Year Ended December 31,
	2025		2024
Stock options		2,925		3,101
Stock warrants		1,623,179		183,411
Restricted stock units		20,000		-
Preferred stock: Series B		2		2

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Significant Accounting Policies [Text Block]

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

Use of Estimates

Discontinued Operations

Cash

Fair Value Measurements

Level 1 – Observable inputs such as quoted prices in active markets;

Level 2 – Inputs other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3 – Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

Receivables

Concentration of Credit Risk

Digital Assets

The Company’s digital assets primarily include holdings of ATH, which are measured at fair value in accordance with ASC 350-60, Intangibles – Goodwill and Other, Crypto Assets.

Refer to Note 5 – Digital Assets for additional information.

Digital Asset Receivable

Property and Equipment

	Years
Computers, software, and office equipment		3	-	10
Leasehold improvements (1)		1	-	2
Laboratory equipment		4	-	10

(1)

Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Long-lived Assets

Leases

Revenue Recognition

Revenues from Services

Contract Balances

Practical Expedients

Stock-Based Compensation

Research and Development

Income Taxes

Tax years after 2005 remain open to examination by federal and state tax authorities due to unexpired net operating loss carryforwards.

Loss per Share

Risks and Uncertainties

The Company is subject to various risks including market risk, liquidity risk and other risks related to its concentration in ATH.

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

Note 4 - Contracts With Customers (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Accounts Receivable, after Allowance for Credit Loss, Current	$ 32,120	$ 34,154
Accounts Receivable, Allowance for Credit Loss, Current	0	0
Contract with Customer, Liability	144,076	$ 224,076
Contract with Customer, Liability, Revenue Recognized	$ 80,000

Note 11 - Stockholders' Equity - Warrant Valuation Assumption (Details)	Dec. 31, 2025	Dec. 31, 2024
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input	0	0
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Price Volatility [Member]
Warrants measurement input		0.973
Warrants and Rights Outstanding, Measurement Input		0.973
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Warrants measurement input	0.994
Warrants and Rights Outstanding, Measurement Input	0.994
Measurement Input, Price Volatility [Member] \| Maximum [Member]
Warrants measurement input	1.035
Warrants and Rights Outstanding, Measurement Input	1.035
Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Warrants measurement input	0.0371	0.0406
Warrants and Rights Outstanding, Measurement Input	0.0371	0.0406
Measurement Input, Risk Free Interest Rate [Member] \| Maximum [Member]
Warrants measurement input	0.0437	0.0458
Warrants and Rights Outstanding, Measurement Input	0.0437	0.0458
Measurement Input, Expected Term [Member]
Warrants measurement input	5
Warrants and Rights Outstanding, Measurement Input	5
Measurement Input, Expected Term [Member] \| Minimum [Member]
Warrants measurement input		1.5
Warrants and Rights Outstanding, Measurement Input		1.5
Measurement Input, Expected Term [Member] \| Maximum [Member]
Warrants measurement input		5
Warrants and Rights Outstanding, Measurement Input		5

Consolidated Balance Sheets - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 10,790,850	$ 611,822
Accounts receivable, net	32,120	34,154
Prepaid expense and other assets	280,904	318,539
Crypto assets at fair value	24,439,598	0
Digital asset receivable	7,226,475	0
Current assets of discontinued operations	0	1,261,403
Total current assets	42,769,947	2,225,918
Locked crypto receivable at fair value, net of current portion	8,258,681	0
Property and equipment, net	223,128	347,588
Lease right-of-use assets	1,487,703	2,047,241
Other long-term assets	148,887	149,433
Non-current assets of discontinued operations	0	202,337
Total assets	52,888,346	4,972,517
Current liabilities:
Accounts payable	1,840,608	1,044,394
Note payable	107,951	0
Accrued expenses and other liabilities	1,520,518	1,236,378
Contract liabilities	144,076	224,076
Lease liability	653,743	555,169
Current liabilities of discontinued operations	0	533,384
Total current liabilities	4,266,896	3,593,401
Lease liability – net of current portion	904,495	1,558,239
Non-current liabilities of discontinued operations	0	23,487
Total liabilities	5,171,391	5,175,127
Stockholders’ equity (deficit):
Common stock, $.01 par value, 200,000,000 shares authorized, 4,083,173 and 444,475 shares outstanding as of December 31, 2025, and December 31, 2024, respectively	40,832	4,445
Additional paid-in capital	461,196,805	180,218,424
Accumulated deficit	(413,521,474)	(180,426,271)
Total stockholders’ equity (deficit)	47,716,955	(202,610)
Total liabilities and stockholders’ equity (deficit)	52,888,346	4,972,517
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficit):
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of December 31, 2025, and December 31, 2024	$ 792	$ 792

Note 8 - Leases (Tables)

12 Months Ended

Dec. 31, 2025

Lease, Cost [Table Text Block]

	December 31, 2025			December 31, 2024
Weighted average remaining lease term – operating leases in years		2.16			3.16
Weighted average discount rate – operating leases		13	%		13	%

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

2026		803,724
2027		827,909
2028		139,022
Total lease payments		1,770,655
Less: interest		(212,417	)
Present value of lease liabilities	$	1,558,238

Note 6 - Fair Value Measurements - Fair Value of Assets and Liabilities on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Fair Value	$ 24,439,598
Embedded derivative related to digital asset receivable	77,893,482
Fair Value, Inputs, Level 1 [Member]
Fair Value	24,439,598
Fair Value, Inputs, Level 2 [Member]
Fair Value	0
Fair Value, Inputs, Level 3 [Member]
Fair Value	0
Embedded derivative related to digital asset receivable	$ 77,893,482
Money Market Funds [Member]
Money market funds		$ 300,000
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Money market funds		300,000
Money Market Funds [Member] \| Fair Value, Inputs, Level 2 [Member]
Money market funds		0
Money Market Funds [Member] \| Fair Value, Inputs, Level 3 [Member]
Money market funds		$ 0

Note 10 - Note Payable (Details Textual) - Insurance Policy Financing [Member]	1 Months Ended
	Jun. 30, 2025 USD ($)	Jun. 30, 2024	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Debt Instrument, Face Amount	$ 264,048			$ 275,098
Debt Instrument, Number of Monthly Installment	10	10
Short-Term Debt, Percentage Bearing Fixed Interest Rate	6.60%			8.00%
Notes Payable			$ 107,951	$ 0

Note 5 - Digital Assets (Tables)

12 Months Ended

Dec. 31, 2025

Crypto Asset, Holding [Table Text Block]

		Units Held				Cost Basis				Fair Value
ATH			2,837,163,868			$	101,258,178			$	24,439,334

Crypto Asset, Activity [Table Text Block]

	For the Year Ended December 31, 2025
Fair Value, January 1, 2025	$	-
Unlocked ATH received from investors		62,973,982
ATH contributed by DCI pursuant to Side Letter		2,230,949
ATH claimed from digital asset receivable		3,445,865
Purchases of ATH		32,607,382
Disposals		-
Unrealized gain / (loss)		(76,818,844	)
Fair Value, December 31, 2025	$	24,439,334

Note 11 - Stockholders' Equity

12 Months Ended

Dec. 31, 2025

Equity [Text Block]

NOTE 11 – STOCKHOLDERS’ EQUITY

Registered Direct Offering

On February 18, 2025, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors for the sale by the Company of 24,223 shares (the “Registered Direct Offering Shares”) of the Company’s common stock, par value $0.01 per share, at a purchase price of $22.50 per share, in a registered direct offering. The offering closed on February 19, 2025. The gross proceeds to the Company from the offering were approximately $545,000, before deducting the placement agent’s fees and other offering expenses. The Registered Direct Offering Shares were offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-279123).

The Company agreed to pay H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent, an aggregate fee equal to 7.0% of the gross proceeds received by the Company from the sale of the securities in the offering as well as a management fee equal to 1.0% of such gross proceeds, and $15,000 for fees and expenses of legal counsel. The Company also issued to Wainwright, or its designees, warrants to purchase up to 7.0% of the aggregate number of shares of the Company’s common stock sold in the transactions, or warrants to purchase up to an aggregate of 1,698 shares of the Company’s common stock (the “Registered Direct Offering Placement Agent Warrants”). The Registered Direct Offering Placement Agent Warrants are exercisable for five years from the commencement of sales in the offering and have an exercise price equal to 125% of the purchase price of shares of the Company’s common stock sold in the offering, or $28.13 per share. The Registered Direct Offering Placement Agent Warrants and the shares issuable upon exercise of the Registered Direct Offering Placement Agent Warrants were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and in reliance on similar exemptions under applicable state laws.

Renovaro Subscription Agreement

On March 13, 2025, the Company executed a share subscription agreement with Renovaro, pursuant to the Extension Agreement dated February 28, 2025, that amended the previous LOI between the parties. Pursuant to the share subscription agreement, Renovaro subscribed to purchase and the Company sold to Renovaro 31,153 unregistered shares of the Company’s common stock at a price of $16.05 per share for a total purchase price of $500,000. The closing of this share issuance occurred on March 17, 2025.

May 2025 Private Placement

On May 13, 2025, the Company executed a share subscription agreement with an institutional and accredited investor for the sale, in a private placement, by the Company of 18,692 shares of the Company’s common stock at a price of $16.05 per share for a total purchase price of $300,000. The closing of this share issuance occurred on June 3, 2025.

At The Market Offering

On May 3, 2024, the Company entered into an ATM Sales Agreement (the “Sales Agreement”) with Wainwright, pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of its common stock through an “at the market offering” program pursuant to which Wainwright will act as sales agent. Subject to the terms and conditions of the Sales Agreement, Wainwright is permitted to sell the shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Sales Agreement provides that Wainwright will be entitled to compensation for its services of 3.0% of the gross sales price of all shares sold through Wainwright under the Sales Agreement. The Company is subject to certain restrictions on its ability to offer and sell shares of its common stock under the Sales Agreement.

On May 6, 2024, following execution of the Sales Agreement, the Company filed with the SEC a shelf registration statement on Form S-3 (the “May 2024 Shelf Registration Statement”). The May 2024 Shelf Registration Statement, as amended, was declared effective by the SEC on May 21, 2024 and included a prospectus supplement (the “Initial ATM Prospectus Supplement”) to the base prospectus related to the offering of up to $3,696,000 of shares of the Company’s common stock under the Sales Agreement. As of May 31, 2024, the Company had offered and sold 107,140 shares of common stock under the Initial ATM Prospectus Supplement for gross proceeds of approximately $3,696,000. The net proceeds from the shares offered and sold in May 2024, after deducting commissions and offering expenses, were approximately $3,122,000.

On April 18, 2025, in accordance with the terms of the Sales Agreement, the Company filed a prospectus supplement to the May 2024 Shelf Registration Statement relating to the offer and sale of up to an additional $1,491,000 of shares of the Company’s common stock.

On June 2, 2025, in accordance with the terms of the Sales Agreement, the Company determined to further increase the number of shares it may sell under the Sales Agreement, from the approximately $1,352,000 remaining as of May 31, 2025 up to an aggregate of $3,398,000, and the Company filed an additional prospectus supplement with the SEC on June 2, 2025.

On October 29, 2025, in accordance with the terms of the Sales Agreement, the Company determined to further increase the number of shares it may sell under the Sales Agreement, from the approximately $2,292,000 remaining as of September 30, 2025 up to an aggregate of $18,330,000, and the Company filed an additional prospectus supplement with the SEC on October 29, 2025.

As of December 31, 2025, approximately $18,330,000 remained available to the Company for sales under the Sales Agreement.

During the year ended December 31, 2025, the Company issued and sold 139,680 shares of common stock under the Sales Agreement resulting in net proceeds to the Company of approximately $1,530,000 after deducting approximately $342,000 in issuance costs.

Standby Equity Purchase Agreement

On July 1, 2025, the Company entered into a standby equity purchase agreement (the “SEPA”) with YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville”). Pursuant to the SEPA, the Company has the right to sell to Yorkville up to $10 million in shares of its common stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. Sales of the shares of common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company’s option, and the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA. In connection with the execution of the SEPA, the Company issued 8,033 shares of its common stock to Yorkville as consideration for its commitment to purchase the Company’s common stock pursuant to the SEPA.

The Company has the right, but not the obligation, from time to time at its discretion until the first day of the month following the 36-month period after the date of the SEPA, to direct Yorkville to purchase a specified number of shares of the Company’s common stock (each such sale, an “Advance”) by delivering written notice to Yorkville (each, an “Advance Notice”). The per share purchase price for the shares of common stock, if any, that the Company elects to sell to Yorkville in an Advance pursuant to the SEPA will be determined by reference to the volume weighted average price of the Company’s common stock (the “VWAP”) and calculated in accordance with the SEPA, less a discount of 4.0%. The Company filed a registration statement on Form S-1 for the resale of up to 128,114 shares by Yorkville on July 18, 2025, which was declared effective by the SEC on July 28, 2025.

On September 19, 2025, the Company received approval from its stockholders to issue shares of its common stock to Yorkville under the SEPA in excess of 19.99% of the number of shares of common stock outstanding as of the date of the SEPA (the “Exchange Cap”). Yorkville is not obligated to purchase or acquire, and shall not purchase or acquire, any shares of common stock under the SEPA which, when aggregated with all other shares of the Company’s common stock then beneficially owned by Yorkville and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by Yorkville and its affiliates exceeding 4.99% of the then outstanding voting power or number of shares of the Company’s common stock.

As of December 31, 2025, the Company had sold no shares pursuant to the SEPA.

August 2025 Private Placement

On August 26, 2025, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it sold and issued 36,237 shares of its common stock, at a purchase price of $11.40 per share, in a private placement transaction. This offering closed on August 26, 2025 and the Company received gross proceeds of $413,093.

September 2025 Private Placements and Related Agreements

On September 29, 2025, the Company entered into a securities purchase agreement (the “Crypto SPA”) with certain accredited investors pursuant to which the Company agreed to sell and issue to such investors in a private placement (the “Crypto PIPE Offering”) pre-funded warrants (the “Crypto PIPE Warrants”). Also on September 29, 2025, the Company entered into a securities purchase agreement (the “Cash SPA,” and together with the Crypto SPA, the “September SPAs”), pursuant to which it agreed to sell and issue to certain accredited investors, in exchange for cash (the “Cash PIPE Offering,” and together with the Crypto PIPE Offering, the “PIPE Offerings”), the Company’s common stock and warrants (the “Cash PIPE Warrants”). The PIPE Offerings closed October 7, 2025 (the “Closing Date”).

Cash PIPE and Crypto PIPE

In the Cash PIPE Offering, the Company sold an aggregate of 4,366,703 shares of common stock (or pre-funded warrants at a nominal $0.01 exercise price per share to purchase shares of common stock, in lieu thereof) to certain accredited investors for $11.6265 per share. Aggregate Cash PIPE Offering proceeds were $50.8 million before issuance fees and expenses.

In the Crypto PIPE, the Company issued, to certain accredited investors, Crypto PIPE Warrants to purchase up to 14,903,393 shares of its common stock at a nominal $0.01 exercise price per share. As consideration for the Crypto PIPE Warrants, the Company received ATH from purchasers, including tokens with certain restrictions (see “Locked ATH” as defined below), with an aggregate notional value and discounted value of $292.7 million and $173.3 million, respectively.

The Crypto SPA was determined to meet the definition of a derivative in accordance with ASC 815. The settlement amount of the derivative was affected by changes in the USD value of ATH contributed by investors between the effective date of the Crypto SPA on September 29, 2025, and the Closing Date. Because the Crypto SPA obligated the Company to issue a fixed number of shares while the settlement value of those shares was indexed to the price of ATH, the Crypto SPA was classified as a derivative liability and the Company recorded a liability as of September 29, 2025, at its then-fair value with the offsetting entry to earnings. The derivative liability was remeasured as of October 7, 2025 immediately prior to settlement, resulting in a $52.7 million loss recognized within earnings and presented on the consolidated statement of net loss for the year ended December 31, 2025 within “Gain (loss) on derivative instruments.” The derivative liability was fully settled when the Crypto PIPE Offering closed on October 7, 2025, on which date the purchasers in the Crypto PIPE Offering tendered ATH to the Company and the Company issued the Crypto PIPE Warrants to purchasers.

There were 639,449 pre-funded warrants exercised during the year ended December 31, 2025, and the total number of pre-funded warrants outstanding was 16,119,095 as of December 31, 2025, all of which were vested and exercisable and have no expiration date.

Wainwright Engagement Agreement

In connection with the PIPE Offerings, on October 7, 2025, the Company issued five-year warrants (the “Placement Agent Warrants”) to Wainwright, which was the exclusive placement agent for the transactions. The Placement Agent Warrants entitle Wainwright or its designees to purchase up to 218,335 shares of the Company’s common stock (the “Placement Agent Warrant Shares”), which number of Placement Agent Warrant Shares is equal to 5% of the shares of common stock and Cash Pre-Funded Warrants issued in the Cash PIPE, at an exercise price of $11.6265 per share. The Placement Agent Warrants had a grant date fair value of approximately $2.5 million, which were accounted for as an incremental offering cost and netted against the proceeds from the Cash PIPE. The Company also paid to Wainwright a cash fee of approximately $2.5 million, or 5% of gross cash proceeds of the PIPE Offerings.

Strategic Advisor Agreement and Asset Management Agreement

In connection with the Treasury Strategy, on October 7, 2025, the Company entered into a strategic advisor agreement (the “Strategic Advisor Agreement”) under which it engaged DNA as a strategic advisor to provide financial advisory services related to digital asset strategies and business development initiatives. As compensation for DNA’s services, the Company issued five-year warrants (the “Strategic Advisor Warrants”) to DNA to purchase up to 1,348,906 shares of its common stock at an exercise price of $11.6265 per share. The Company further engaged DNA under a 10-year asset management agreement (the “Asset Management Agreement”), pursuant to which DNA will act as the Company’s asset manager with respect to its digital assets. As compensation for its services under the Asset Management Agreement, DNA is entitled to a 1.00% per annum asset-based management fee, plus an incentive fee equal to 25% of profits earned on managed assets over 7%. See Note 13 – Related Parties for further discussion.

Warrant Inducement Transaction

On July 25, 2024, the Company entered into definitive agreements with certain of its existing warrant holders for the exercise of warrants to purchase an aggregate of 63,874 shares of its common stock having a current exercise price of $210.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $19.80 per share. The gross proceeds to the Company from the exercise of the existing warrants were approximately $1,265,000, prior to deducting placement agent fees and transaction expenses payable by the Company. The reduction of the exercise price represented a modification to the existing warrants, which was recognized as an equity issuance cost of $594,033 charged against the proceeds of the offering.

In consideration for the immediate cash exercise of the warrants, the Company concurrently issued to the warrant holders new unregistered Series A warrants to purchase up to 63,874 shares of common stock (the “Series A Warrants”) and new Series B warrants to purchase up to 63,874 shares of common stock (the “Series B Warrants”). The Series A Warrants and the Series B Warrants have an exercise price of $16.05 per share and are exercisable immediately upon issuance. The Series A Warrants have a term equal to five years from the date of issuance, and the Series B Warrants have a term equal to 18 months from the date of issuance.

The transactions described above closed on July 26, 2024. Wainwright acted as the exclusive placement agent for the above-mentioned transactions. The Company paid Wainwright as consideration (i) an aggregate cash fee equal to 7.0% of the gross proceeds from the exercise of the existing warrants, (ii) a management fee equal to 1.0% of the aggregate gross proceeds from the exercise of the existing warrants, (iii) $35,000 for expenses, and (iv) $15,950 for clearing fees. Additionally, the Company issued to Wainwright (or its designees) as compensation, warrants to purchase up to 4,473 shares of common stock of the Company (equal to 7.0% of the aggregate number of existing warrants exercised in the offering) (the “Warrant Inducement Placement Agent Warrants”). The Warrant Inducement Placement Agent Warrants have a term of five years from the closing of the offering and an exercise price of $24.75 per share.

Stock Warrants

The following summarizes transactions for warrants for the period indicated, excluding pre-funded warrants:

	Number of Shares			Weighted-Average Exercise Price
Outstanding as of December 31, 2024		183,411		$	133.80
Issued		1,568,939			11.64
Expired		(29,112	)		447.36
Exercised		(100,059	)		16.05
Outstanding as of December 31, 2025		1,623,179		$	17.39

During the year ended December 31, 2025, warrant holders exercised warrants for an aggregate of 100,059 shares of the Company’s common stock at an average exercise price of $16.05 for approximately $1,606,000 of gross proceeds. The shares issued upon exercise of the warrants were registered on a registration statement on Form S-3, which was declared effective on August 23, 2024.

The Company determines the grant date fair value of warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term.

The fair value of each warrant grant during the year ended December 31, 2025 and 2024 was estimated on the grant date using the Black-Scholes option valuation model with the following assumptions, excluding pre-funded warrants:

	Year Ended December 31,
	2025			2024
Expected dividend yield		0.0	%		0.0	%
Expected stock price volatility		99.4% - 103.5	%		97.3	%
Risk-free interest rate		3.71% - 4.37	%		4.06% –4.58	%
Expected life (in years)		5			1.5 –5

The following summarizes the status of warrants outstanding as of December 31, 2025, excluding pre-funded warrants:

Range of Exercise Prices		Shares		Weighted Average Remaining Life
$	11.63 –16.05		1,594,935		4.72
$	24.75 –28.13		6,171		3.73
$	210.00 –240.00		8,221		1.39
$	300.00 –731.25		13,852		0.51
Total			1,623,179

Warrants expire on various dates from January 2026 to October 2030.

The following table is the listing of outstanding warrants as of December 31, 2025, by year of grant, excluding pre-funded warrants:

Year	Shares		Range of Exercise Prices
2021		15,733		240.00	–		731.25
2022		6,340		210.00	–		225.00
2023		-		-	–		-
2024		32,167		16.05	–		24.75
2025		1,568,939		11.63	–		28.13
Total		1,623,179	$	11.63	–	$	731.25

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Note 15 - Retirement Savings Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Contribution Amount	$ 76,858	$ 125,328
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 11 - Stockholders' Equity - Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Shares, warrants (in shares) \| shares	1,623,179
Minimum [Member]
Price, warrants (in dollars per share)	$ 11.63
Maximum [Member]
Price, warrants (in dollars per share)	$ 731.25
Warrant One [Member]
Shares, warrants (in shares) \| shares	1,594,935
Weighted average remaining life, warrants (Year)	4 years 8 months 19 days
Warrant One [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 11.63
Warrant One [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 16.05
Warrant Two [Member]
Shares, warrants (in shares) \| shares	6,171
Weighted average remaining life, warrants (Year)	3 years 8 months 23 days
Warrant Two [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 24.75
Warrant Two [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 28.13
Warrant Three [Member]
Shares, warrants (in shares) \| shares	8,221
Weighted average remaining life, warrants (Year)	1 year 4 months 20 days
Warrant Three [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 210
Warrant Three [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 240
Warrant Four [Member]
Shares, warrants (in shares) \| shares	13,852
Weighted average remaining life, warrants (Year)	6 months 3 days
Warrant Four [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 300
Warrant Four [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 731.25

Note 3 - Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Disposal Group by Balance Sheet Classification [Table Text Block]

	December 31, 2025		December 31, 2024
Assets:
Cash	$	-	$	122,851
Accounts receivable, net		-		746,266
Inventories		-		339,968
Prepaid expense and other assets		-		52,318
Total current assets of discontinued operations		-		1,261,403

Property and equipment, net		-		21,882
Intangibles, net		-		159,158
Lease right-of-use assets		-		17,266
Other long-term assets		-		4,031
Total assets of discontinued operations	$	-	$	1,463,740

Liabilities:
Accounts payable	$	-	$	97,780
Accrued expenses and other liabilities		-		248,086
Contract liabilities		-		80,909
Lease liability		-		106,609
Total current liabilities of discontinued operations		-		533,384

Lease liability – net of current portion		-		-
Other long-term liabilities		-		23,487
Total liabilities	$	-	$	556,871

Disposal Groups, Including Discontinued Operations [Table Text Block]

	Year Ended December 31,
	2025			2024
Revenue	$	157,179		$	1,571,795
Cost of sales		122,800			751,147
Gross profit from discontinued operations		34,379			820,648

Operating expenses:
General and administrative		209,550			1,039,950
Operations, research and development		126,505			1,115,595
Sales and marketing		130,318			637,400
Total operating expenses		466,373			2,792,945
Total operating (loss) from discontinued operations		(431,994	)		(1,972,297	)
Gain (loss) on disposal of discontinued operations		172,451			(463,127	)
Other income (expense)		17,987			(4,309	)
Net (loss) from discontinued operations	$	(241,556	)	$	(2,439,733	)

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

Note 11 - Stockholders' Equity - Disclosure of Warrant Information (Details)	Dec. 31, 2025 $ / shares shares
Shares, warrants (in shares) \| shares	1,623,179
Minimum [Member]
Price, warrants (in dollars per share)	$ 11.63
Maximum [Member]
Price, warrants (in dollars per share)	$ 731.25
Warrants 2021 [Member]
Shares, warrants (in shares) \| shares	15,733
Warrants 2021 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 240
Warrants 2021 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 731.25
Warrants 2022 [Member]
Shares, warrants (in shares) \| shares	6,340
Warrants 2022 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 210
Warrants 2022 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 225
Warrants 2023 [Member]
Shares, warrants (in shares) \| shares	0
Warrants 2023 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 0
Warrants 2023 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 0
Warrants 2024 [Member]
Shares, warrants (in shares) \| shares	32,167
Warrants 2024 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 16.05
Warrants 2024 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 24.75
Warrants 2025 [Member]
Shares, warrants (in shares) \| shares	1,568,939
Warrants 2025 [Member] \| Minimum [Member]
Price, warrants (in dollars per share)	$ 11.63
Warrants 2025 [Member] \| Maximum [Member]
Price, warrants (in dollars per share)	$ 28.13

Note 2 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Property Plant and Equipment Useful Life [Table Text Block]

	Years
Computers, software, and office equipment		3	-	10
Leasehold improvements (1)		1	-	2
Laboratory equipment		4	-	10

Note 11 - Stockholders' Equity (Details Textual) - USD ($)								1 Months Ended	12 Months Ended
	Oct. 07, 2025	Aug. 26, 2025	Jul. 01, 2025	May 13, 2025	Mar. 13, 2025	Feb. 18, 2025	Jul. 25, 2024	May 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Oct. 29, 2025	Sep. 30, 2025	Jul. 19, 2025	Jul. 18, 2025	Jun. 02, 2025	May 31, 2025	Apr. 18, 2025	May 03, 2024
Common Stock, Par or Stated Value Per Share									$ 0.01	$ 0.01
Proceeds from Issuance of Common Stock									$ 56,005,986	$ 4,960,562
Payments of Stock Issuance Costs									4,048,995	870,960
Percent of Outstanding Common Stock	5.00%
Proceeds from Issuance of Private Placement	$ 50,800,000
Aggregate Notional Value	292,700,000
Discounted Value	$ 173,300,000
Unrealized Gain (Loss) on Derivatives									$ (52,700,000)
Class of Warrant or Right, Outstanding (in shares)									1,623,179
Asset Management Agreement Term	10
Asset Based Management Fee, Percent	1.00%
Incentive Fee, Percent	25.00%
Managed Assets Profits, Incentive Trigger Percentage	7.00%
Renovaro Acquisition [Member]
Shares Issued, Price Per Share					$ 16.05
Stock Issued During Period, Shares, Acquisitions					31,153
Stock Issued During Period, Value, Acquisitions					$ 500,000
Registered Direct Offering, Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,698
Warrants and Rights Outstanding, Term						5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price						125.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 28.13
Cash PIPE Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Crypto PIPE Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	14,903,393
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Prefunded Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)									639,449
Class of Warrant or Right, Outstanding (in shares)									16,119,095
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	218,335						4,473
Warrants and Rights Outstanding, Term	5 years						5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.6265						$ 24.75
Class of Warrant or Right, Grant Date Fair Value	$ 2,500,000
Warrants or Rights, Commissions	$ 2,500,000
Warrants or Rights, Commissions, Percent	5.00%						7.00%
Warrants or Rights, Management Fee, Percent							1.00%
Warrants or Rights, Issuance Expenses							$ 35,000
Warrants or Rights, Clearing Fees							$ 15,950
Warrants or Rights, Placement Agent Fee, Percent							7.00%
Strategic Advisor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,348,906
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.6265
Class of Warrant or Right, Grant Date Fair Value	$ 15,400,000
The February 2021, June 2021, and May 2022 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							63,874
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 210
Payments of Stock Issuance Costs							$ 594,033
Class of Warrant or Right, Exercised During Period, Exercise Price							$ 19.8
Proceeds from Warrant Exercises							$ 1,265,000
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							63,874
Warrants and Rights Outstanding, Term							5 years
Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							63,874
Warrants and Rights Outstanding, Term							18 months
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 16.05
Stock Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)									100,059
Class of Warrant or Right, Exercised During Period, Exercise Price									$ 16.05
Proceeds from Warrant Exercises									$ 1,606,000
February 18, 2025 Offering [Member]
Stock Issued During Period, Shares, New Issues						24,223
Common Stock, Par or Stated Value Per Share						$ 0.01
Shares Issued, Price Per Share						$ 22.5
Proceeds from Issuance of Common Stock						$ 545,000
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds						7.00%
Sale of Stock, Management Fee, Percent of Gross Proceeds						1.00%
Professional Fees						$ 15,000
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold						7.00%
May 2025 Private Placement [Member]
Stock Issued During Period, Shares, New Issues				18,692
Shares Issued, Price Per Share				$ 16.05
Stock Issued During Period, Value, New Issues				$ 300,000					$ 300,000
Sales Agreement [Member]
Stock Issued During Period, Shares, New Issues								107,140	139,680
Proceeds from Issuance of Common Stock								$ 3,696,000
Stock Issued During Period, Value, New Issues										$ 3,122,002
Sale of Stock, Commissions, Percent																		3.00%
Sale of Stock, Maximum Amount									$ 18,330,000		$ 18,330,000				$ 3,398,000			$ 3,696,000
Net Proceeds from Issuance of Common Stock								$ 3,122,000	1,530,000
Sale of Stock, Additional Amount																	$ 1,491,000
Sale of Stock, Remaining Available Balance												$ 2,292,000				$ 1,352,000
Payments of Stock Issuance Costs									$ 342,000
Standby Equity Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues			8,033
Sale of Stock, Maximum Amount			$ 10,000,000
Sale of Stock, Discount Rate			4.00%
Sale of Stock, Maximum Shares														128,114
Percent of Outstanding Common Stock													19.99%
Sale of Stock, Beneficial Ownership Voting Power													4.99%
August 26, 2025 Offering [Member]
Stock Issued During Period, Shares, New Issues		36,237
Shares Issued, Price Per Share		$ 11.4
Proceeds from Issuance of Common Stock		$ 413,093
Cash PIPE SPA [Member]
Stock Issued During Period, Shares, New Issues	4,366,703
Shares Issued, Price Per Share	$ 11.6265

Note 12 - Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Non-vested RSUs as of December 31, 2024, shares (in shares)	0
Non-vested RSUs as of December 31, 2024, average exercise price (in dollars per share)	$ 118,400	$ 0
Granted, number of shares (in shares)	80,101
Granted, weighted-average grant date fair value (in dollars per share)		1,037,897
Vested, number of shares (in shares)	(60,101)
Vested, weighted-average grant date fair value (in dollars per share)		$ 919,497
Non-vested RSUs as of September 30, 2025, shares (in shares)	20,000	0
Non-vested RSUs as of September 30, 2025, average exercise price (in dollars per share)		$ 118,400

Note 5 - Digital Assets (Details Textual) - Aethir (ATH) [Member]	12 Months Ended
	Dec. 31, 2025 USD ($)	Oct. 07, 2025
Crypto Asset, Number of Units	2,837,163,868
Crypto Asset, Cost	$ 101,258,178
Crypto Assets, Open Market Purchases	1,180,000,000
Crypto Asset, Receivable	$ 15,500,000
Crypto Asset, Host Receivable	93,400,000
Embedded Derivative, Fair Value of Embedded Derivative Asset	77,900,000
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net	$ (77,900,000)
Side Letter Agreement [Member]
Bonus Tokens, Percent		20.00%
Crypto Asset, Number of Units	236,000,000
Crypto Asset, Cost	$ 2,200,000

Note 1 - Organization (Details Textual)	12 Months Ended
Note 1 - Organization (Details Textual)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Number of Tumor Samples	150,000
Cash and Cash Equivalent	$ 10,790,850	$ 611,822
Crypto Asset, Fair Value, Current	24,439,598	0
Equity, Attributable to Parent	$ 47,716,955	$ (202,610)	$ 1,966,969	$ 8,271,780
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	15

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

Note 12 - Stock-Based Compensation

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Text Block]

NOTE 12 – STOCK-BASED COMPENSATION

Equity Incentive Plan

On December 30, 2024, the Company’s stockholders approved the 2024 Equity Incentive Plan (the “2024 Plan”). The 2024 Plan allows for the issuance of non-statutory stock options and incentive stock options, stock appreciation rights, stock awards, restricted stock, restricted stock units, and performance awards to employees, directors, and consultants of the Company, where permitted under the plan. Due to the approval of the 2024 Plan, no new awards will be granted under the Company’s Amended and Restated 2012 Stock Incentive Plan. The exercise price for each stock option is determined by the market price on the date of issuance. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options outstanding under this plan have a contractual life of ten years.

ASC 718, Compensation – Stock Compensation (“ASC 718”), requires that a company that issues equity as compensation record compensation expense that corresponds to the estimated cost of those equity grants. ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means.

Restricted Stock Units

On September 9, 2025, the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, determined that it was appropriate to award restricted stock units (“RSUs”) as a form of compensation for employees, consultants and directors and approved a form of Restricted Stock Unit Award Agreement, with such awards to be granted under the Company’s 2024 Plan. Consistent with that determination, the Board of Directors approved the grant of 60,101 RSUs on September 9, 2025, including 8,331 RSUs to Raymond F. Vennare, the Company’s former Chief Executive Officer, 6,467 RSUs to Josh Blacher, the Company’s Chief Financial Officer, and 25,872 RSUs in the aggregate to the Company’s non-executive directors. Each RSU represented the right to receive one share of the Company’s common stock upon vesting. The RSUs contained a service-based vesting condition requiring continued service through October 31, 2025, at which point the RSUs vested in full. The RSUs were settled on November 28, 2025.

On December 10, 2025, the Company entered into an amendment to the employment agreement with Raymond F. Vennare dated as of November 1, 2022. Pursuant to the amendment and following approval by the Compensation Committee, Mr. Vennare was awarded 20,000 RSUs. The RSUs contained a service-based vesting condition requiring continued service through January 1, 2026, at which point the RSUs vest in full.

The following table summarizes the Company’s RSU activity for the period indicated:

	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested RSUs as of December 31, 2024		-		$	-
Granted		80,101			1,037,897
Vested		(60,101	)		919,497
Nonvested RSUs as of December 31, 2025		20,000			118,400

The Company has $5,381 of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized in January 2026.

Stock Options

The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. There were no stock options granted during the years ended December 31, 2025 and 2024.

The following table summarizes the Company’s stock option activity for the period indicated:

	Number of Shares			Weighted-Average Exercise Price
Outstanding as of December 31, 2024		3,101		$	1,240.50
Issued		-			-
Expired		(176	)		20,729.18
Exercised		-			-
Outstanding as of December 31, 2025		2,925		$	1,334.07

The Company has no unrecognized stock-based compensation expense related to stock options that is expected to be recognized in future months.

Stock Compensation to Non-Employees

During the year ended December 31, 2025, the Company issued shares of common stock to certain non-employees as compensation for services provided.

Shares of common stock with a grant date fair value of $100,000 were issued to non-employees in exchange for digital marketing services rendered through August 2025.

Stock warrants with a grant date fair value of $15.4 million were also granted to DNA in exchange for strategic advisory services. The Strategic Advisor Warrants have a five-year term and may be used to purchase up to 1,348,906 shares of the Company’s common stock at an exercise price of $11.6265 per share. See Note 13 – Related Parties for further discussion.

Stock-Based Compensation Expense, Net

Stock-based compensation expense, net of forfeitures, recognized for the years ended December 31, 2025 and 2024 was $16,482,661 and $906, respectively. $15.4 million was recognized as stock-based compensation expense related to the Strategic Advisor Warrants, which were immediately vested and exercisable at the grant date, contained no substantive future service requirement and for which services were substantially rendered in full during the year ended December 31, 2025.

Stock-based compensation expense for the years ended December 31, 2025 and 2024 is recorded within each of the captions comprising Operating expenses. $15.4 million of stock-based compensation expense related to the Strategic Advisor Warrants is recorded within General and administrative expense on the Statement of Net Loss for the year ended December 31, 2025.

The following summarizes the status of options and outstanding as of December 31, 2025:

Range of Exercise Prices		Shares		Weighted Average Remaining Life
$	93.30 –121.80		64		7.02
$	219.75 –375.00		819		4.97
$	393.00 –492.00		896		2.97
$	783.00 –12,750.00		1,146		2.68
Total			2,925

Stock options expire on various dates from March 2026 to April 2033.

The following table is the listing of outstanding stock options as of December 31, 2025, by year of grant:

Stock Options:

Year	Shares		Range of Exercise Prices
2016		25		462.00	–		12,750.00
2017		678		462.00	–		6,300.00
2018		205		462.00	–		3,390.00
2019		903		462.00	–		2,370.00
2020		1,002		219.75	–		492.00
2021		48		375.00	–		399.00
2022		48		115.50	–		219.75
2023		16		93.30	–		93.30
2024		-		-	–		-
2025		-		-	–		-
Total		2,925	$	93.30	–	$	17,250.00

Consolidated Statements of Net Loss - USD ($)	12 Months Ended
Consolidated Statements of Net Loss - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Revenue	$ 125,284	$ 84,812
Gains (losses) on digital assets	(152,490,550)	0
Operating costs and expenses:
Cost of revenues	72,622	78,285
General and administrative	25,924,358	7,235,797
Operations, research and development	2,147,222	2,241,461
Sales and marketing	406,247	833,199
Total operating expenses	28,550,449	10,388,742
Total operating (loss)	(180,915,715)	(10,303,930)
Other income	806,037	89,367
Other expense	(8,969)	(11,468)
Gain (loss) on derivative instruments	(52,735,000)	1,376
Loss from continuing operations	(232,853,647)	(10,224,655)
Loss from discontinued operations	(241,556)	(2,439,733)
Net loss	$ (233,095,203)	$ (12,664,388)
Loss from continuing operations (in dollars per share)	$ (13.36)	$ (28.12)
Loss from discontinued operations (in dollars per share)	(0.01)	(6.71)
Net loss per common share, basic and diluted (in dollars per share)	$ (13.37)	$ (34.83)
Weighted average shares used in computation – basic and diluted (in shares)	17,429,861	363,583

Note 12 - Stock-Based Compensation - Schedule of Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Shares (in shares) \| shares	2,925
Stock Options One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 93.3
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 121.8
Shares (in shares) \| shares	64
Weighted Average Remaining Life (Year)	7 years 7 days
Stock Options Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 219.75
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 375
Shares (in shares) \| shares	819
Weighted Average Remaining Life (Year)	4 years 11 months 19 days
Stock Options Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 393
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 492
Shares (in shares) \| shares	896
Weighted Average Remaining Life (Year)	2 years 11 months 19 days
Stock Options Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 783
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 12,750
Shares (in shares) \| shares	1,146
Weighted Average Remaining Life (Year)	2 years 8 months 4 days

Insider Trading Arrangements	12 Months Ended
Insider Trading Arrangements	Dec. 31, 2025
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement [Text Block]	ITEM 9B. OTHER INFORMATION. None.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 16 - Loss Per Share - Schedule of Earnings Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Net (loss) from continuing operations	$ (232,853,647)	$ (10,224,655)
Loss from discontinued operations	(241,556)	(2,439,733)
Net (loss) attributable to common stockholders	$ (233,095,203)	$ (12,664,388)
Weighted average common shares outstanding - basic (in shares)	17,429,861	363,583
Dilutive effect of stock options, warrants and preferred stock (in shares)	0	0
Weighted average common shares outstanding - diluted (in shares)	17,429,861	363,583
Net (loss) from continuing operations attributable to common stockholders per common share – basic and diluted (in dollars per share)	$ (13.36)	$ (28.12)
Net (loss) from discontinued operations attributable to common stockholders per common share – basic and diluted (in dollars per share)	(0.01)	(6.71)
(Loss) per common share - basic and diluted (in dollars per share)	$ (13.37)	$ (34.83)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Amount after tax of income (loss) from continuing operations attributable to the parent.

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(13))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References + Details

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

Award Timing, How MNPI Considered [Text Block]

Note 3 - Discontinued Operations (Details Textual)	Mar. 14, 2025 USD ($)
Eagan Business [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 625,000

Note 3 - Discontinued Operations - Schedule of Disposal Groups Including Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Less: loss from discontinued operations	$ (241,556)	$ (2,439,733)
Discontinued Operations, Disposed of by Sale [Member] \| Birmingham Laboratory and Eagan Business [Member]
Revenue	157,179	1,571,795
Cost of sales	122,800	751,147
Gross profit from discontinued operations	34,379	820,648
General and administrative	209,550	1,039,950
Operations, research and development	126,505	1,115,595
Sales and marketing	130,318	637,400
Total operating expenses	466,373	2,792,945
Total operating (loss) from discontinued operations	(431,994)	(1,972,297)
Gain/(loss) on disposal of discontinued operations	172,451	(463,127)
Other income	17,987	(4,309)
Less: loss from discontinued operations	$ (241,556)	$ (2,439,733)

Note 18 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($)	Feb. 09, 2026	Feb. 06, 2026
Mr Vennare [Member]
Severance Costs	$ 575,000
Labor and Related Expense, Bonus	$ 287,500
Chief Executive Officer [Member]
Annual Base Salary		$ 575,000
Annual Cash Bonus, Percentage of Base Salary		50.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross		500,000

Note 7 - Property and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Property, Plant, and Equipment Gross	$ 2,029,427	$ 2,169,541
Less: Accumulated depreciation	(1,806,299)	(1,821,953)
Total Property and equipment, net	223,128	347,588
Office Equipment [Member]
Property, Plant, and Equipment Gross	170,350	170,350
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	166,847	306,961
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	$ 1,692,230	$ 1,692,230

Award Timing Disclosure

12 Months Ended

Dec. 31, 2025

Statement [Table]

ITEM 11. EXECUTIVE COMPENSATION.

Overview

This section describes the material elements of the compensation awarded to, earned by or paid to (i) each individual who served as our principal executive officer during 2025, (ii) our two most highly compensated other executive officers who were serving as executive officers at the end of 2025 and who received more than $100,000 in the form of salary and bonus during such year, and (iii) up to two additional individuals for whom disclosure would have been provided pursuant to (ii) above but for the fact that the individual was not serving as an executive officer at the end of 2025. We refer to these individuals as our “Named Executive Officers.” During 2025, Messrs. Vennare and Blacher were our only executive officers. Our Named Executive Officers are:

●

Raymond F. Vennare, former Chief Executive Officer;

●

Josh Blacher, Chief Financial Officer; and

●

Christopher Miglino, Chief Executive Officer and Director

Summary Compensation Table for Fiscal 2025 and 2024

The following table provides information regarding the compensation awarded to or earned by each of the Named Executive Officers during the fiscal years ended December 31, 2025, and December 31, 2024:

Name and Principal Position	Year	Salary		Stock Awards			All Other Compensation	Total Compensation

Raymond F. Vennare, Chief Executive Officer	2025	$	682,486	245,858 (a)		$	287,500	$	1,215,844
	2024	$	525,000	$	-	$	-	$	525,000

Josh Blacher, Chief Financial Officer	2025	$	-	98,940 (b)		$	404,995	$	503,935
	2024	$	-			$	453,940	$	453,940

(a)

Represents the grant-date fair value of RSUs granted to Mr. Vennare, 8,331 RSUs were granted on September 9, 2025 and 20,000 RSUs were granted on December 10, 2025.

(b)

Represents the grant-date fair value of RSUs granted to Mr. Blacher, 6,467 RSUs were granted on September 9, 2025.

Newly Appointed Chief Executive Officer

On February 6, 2026, the Board appointed Christopher Miglino as Chief Executive Officer to succeed Mr. Vennare, and as a member of the Board to fill the vacancy created by Mr. Vennare’s resignation, effective as of February 9, 2026. In connection with Mr. Miglino’s appointment as Chief Executive Officer of the Company, the Company and Mr. Miglino entered into an employment agreement, dated February 9, 2026 (the “Employment Agreement”), which provides for, among other things, payment to Mr. Miglino of an annual base salary equal to $575,000, and at the discretion of the Board’s Compensation Committee (the “Committee”), to receive grants of stock options or other equity awards. Mr. Miglino will also be eligible to participate in the Company’s (i) bonus program with annual cash bonus equal up to 50% of his salary or at the discretion of the Committee, a higher percentage based on his and the Company’s performance, (ii) long-term incentive plan to be adopted and maintained by the Compensation Committee, and (iii) standard employee benefit plans generally available to executive employees of the Company.

Outstanding Equity Awards at Fiscal Year-end for Fiscal 2025

On September 9, 2025, the Company granted 8,331 RSUs to Mr. Vennare and 6,467 RSUs to Mr. Blacher. These RSUs vested on October 31, 2025. There were no other outstanding equity awards held by the named executive officers as of December 31, 2025.

Executive Compensation Components for Fiscal 2025

Base Salary. Base salary is an important element of our executive compensation program as it provides executives with a fixed, regular, non-contingent earnings stream to support annual living and other expenses. As a component of total compensation, we generally set base salaries at levels believed to attract and retain an experienced management team that will successfully grow our business and create stockholder value. We also utilize base salaries to reward individual performance and contributions to our overall business objectives but seek to do so in a manner that does not detract from the executives’ incentive to realize additional compensation through our bonus and equity incentive programs.

The Compensation Committee may recommend adjustments to the Chief Executive Officer’s base salary based upon the Compensation Committee’s review of his current base salary, incentive cash compensation and equity-based compensation, as well as his performance and comparative market data. The Compensation Committee also reviews other executives’ salaries throughout the year, with input from the Chief Executive Officer. The Compensation Committee may recommend adjustments to other executives’ base salary based upon the Chief Executive Officer’s recommendation and the reviewed executives’ responsibilities, experience, and performance, as well as comparative market data.

In utilizing comparative data, the Compensation Committee seeks to recommend salaries for each executive at a level that is appropriate after giving consideration to experience for the relevant position and the executive’s performance. The Compensation Committee reviews performance for both our Company (based upon achievement of strategic initiatives) and each individual executive. Based upon these factors, the Compensation Committee may recommend adjustments to base salaries to better align individual compensation with comparative market compensation, to provide merit-based increases based upon individual or company achievement, or to account for changes in roles and responsibilities.

Bonuses. Bonuses may be paid at the discretion of the Compensation Committee and as approved by the Board of Directors based on the Compensation Committee’s determination of the performance of the executive officer.

Stock Options and Other Equity Grants. Consistent with our compensation philosophies related to performance-based compensation, long-term stockholder value creation and alignment of executive interests with those of stockholders, we may make periodic grants of long-term incentive compensation in the form of stock options or other equity-based incentive awards to our executive officers, directors, and others in the organization.

Stock options provide executive officers, directors, and other employees with the opportunity to purchase common stock at a price fixed on the grant date regardless of future market price. A stock option becomes valuable only if the common stock price increases above the option exercise price and the holder of the option remains employed or appointed during the period required for the option shares to vest. This provides an incentive for an option holder to remain employed or appointed by us. In addition, stock options link employees’ compensation to stockholders’ interests by providing an incentive to increase stockholder value. Under our 2024 Equity Incentive Plan (the “2024 Plan”), which was approved by our stockholders on December 30, 2024 as a successor to our Amended and Restated 2012 Stock Incentive Plan, and which was amended by our Board of Directors and approved by our stockholders on November 25, 2025 to increase the number of shares authorized for issuance thereunder, we may also make grants of common stock, restricted stock, restricted stock units, performance awards, and stock appreciation rights to employees (including officers), directors, consultants, or other independent contractors who provide services to the Company or its subsidiaries. Restricted stock units represent the right to receive shares of our common stock (or, in some cases, the value thereof in cash) upon vesting, with vesting generally being time-based, based on achievement of certain performance metrics, or both. We adopted the 2024 Plan to give us flexibility in the types of awards that we could grant to individuals providing services to the Company. As amended, the 2024 Plan authorizes up to 1,066,667 shares for issuance, plus the number of shares subject to outstanding awards under the 2012 Plan as of December 30, 2024, that are forfeited, expire or otherwise terminate without the issuance of shares after December 30, 2024. As of December 31, 2025, there were stock options to purchase 43,595 shares of common stock outstanding under the 2012 Plan. 980,030 shares remain available for future equity awards.

While we have not adopted a formal policy regarding the timing of stock option grants, we do not time the disclosure of material nonpublic information for the purposes of affecting the value of executive compensation and our practice is that the timing of these grants is not scheduled in a manner that intentionally benefits our executive officers or employees.

Limited Perquisites; Other Benefits. We provide our employees, including our executive officers, with a full complement of employee benefits, including health and dental insurance, short term and long-term disability insurance, life insurance, a 401(k) plan, FSA flex plan and Section 125 plan.

Employment Contracts

Employment Agreement for Chief Executive Officer

Consulting Agreement for Chief Financial Officer Services

In August 2023, we entered into a consulting agreement with Danforth Advisors, LLC pursuant to which Mr. Blacher provides consulting services to us. Mr. Blacher does not receive compensation directly from us.

Potential Payments Upon Termination or Change of Control

Most of our stock option agreements provide for an acceleration of vesting in the event of a change in control as defined in the agreements and in the 2012 Plan under which they were previously issued. Also, see “Employment Contracts” above for a description of certain severance compensation arrangements.

Director Compensation

Effective January 25, 2023, the Board adopted an Amended and Restated Director Compensation Program (the “Compensation Program”). Director compensation under the Compensation Program is limited to non-employee directors (defined as directors who are not employees of Axe Compute or any subsidiary and who do not receive regular long-term cash compensation as consultants). Pursuant to the Compensation Program, non-employee directors receive a combination of quarterly and annual awards as compensation for their services as directors. During 2025, cash payments were made in lieu of certain quarterly awards of common stock due to limited availability of shares available for issuance under the 2024 Plan.

The compensation program pays all of the compensation in the form of stock and cash awards (with the cash component payable in additional shares at the election of the director). The cash component is approximately equal to 28% of the total value of the award (or 38.9% of the share component of the award), intended to pay taxes on the full award.

Each director receives a quarterly award of $8,333 payable on the last day of the quarter, consisting of (i) shares with a value of $6,000 and (ii) $2,333 in cash (or additional shares).

Each director who is continuing to serve as a director as of June 17 of a given year also receives an annual award of $10,000, consisting of (i) newly issued shares of common stock with a value of $7,000 and (ii) $3,000 in cash (or additional shares). The awards are payable on or about June 17 each year.

For each board committee, each director receives an additional annual award of $11,112, consisting of (i) shares with a value of $8,000 and (ii) $3,112 in cash (or additional shares), payable on December 31.

If the chairman of the Board is an independent director, the chairman receives an additional annual award of $20,835, consisting of (i) shares with a value of $15,000 and (ii) $5,835 in cash (or additional shares), payable on December 31.

The Lead Independent Director, as voted by the Board of Directors, also receives an annual award of $11,112, consisting of (i) shares with a value of $8,000 and (ii) $3,112 in cash (or additional shares).

Director Compensation Table for Fiscal 2025

The following table summarizes the compensation earned by or paid to each individual who served as a director during the fiscal year ended December 31, 2025:

	Fees Paid or Earned in Cash		Stock Awards (1)		Option Awards		Total
Charles Nuzum Sr. (2)	$	52,892	$	71,451	$	-	$	124,343
Daniel Handley (3)	$	40,444	$	39,448	$	-	$	79,892
Greg St. Clair Sr. (4)	$	43,556	$	47,449	$	-	$	91,005
Nancy Chung-Welch (5)	$	57,501	$	25,441	$	-	$	82,942
Matthew J. Hawryluk (6)	$	43,556	$	47,449	$	-	$	91,005
Veena Rao (7)	$	56,668	$	55,449	$	-	$	102,117
Shawn Matthews (8)	$	2,333	$	6,006	$	-	$	8,339

(1)	Represents grant date fair value of stock awards granted during 2025 as determined pursuant to FASB ASC 718, Stock Compensation.
(2)	Reflects 10,747 shares of common stock received in 2025 for serving on the Board.
(3)	Reflects 5,152 shares of common stock received in 2025 for serving on the Board.
(4)	Reflects 5,152 shares of common stock received in 2025 for serving on the Board.
(5)	Reflects 4,312 shares of common stock received in 2025 for serving on the Board.
(6)	Reflects 5,152 shares of common stock received in 2025 for serving on the Board.
(7)	Reflects 5,152 shares of common stock received in 2025 for serving on the Board.
(8)	Reflects 840 shares of common stock received in 2025 for serving on the Board.

Award Timing MNPI Considered [Flag]

false

Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 35
-Paragraph 12A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479165/842-20-35-12A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-24

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 23
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 310
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477802/946-310-45-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477796/946-210-45-4

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12)(b)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(13)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(13)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(6)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(a)(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(3)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(6)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(6)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(6)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(a)(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(7)(c)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 54: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-3

Note 13 - Related Parties (Details Textual)		3 Months Ended
Note 13 - Related Parties (Details Textual)	Oct. 07, 2025 USD ($) $ / shares shares	Dec. 31, 2025 USD ($)
Asset Management Agreement Term	10
Asset Based Management Fee, Percent	1.00%
Incentive Fee, Percent	25.00%
Managed Assets Profits, Incentive Trigger Percentage	7.00%
Asset Management Fees, Total		$ 722,390
Strategic Advisor Warrants [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	1,348,906
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 11.6265
Class of Warrant or Right, Grant Date Fair Value	$ 15,400,000

Note 12 - Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

	Number of Shares			Weighted-Average Grant Date Fair Value
Nonvested RSUs as of December 31, 2024		-		$	-
Granted		80,101			1,037,897
Vested		(60,101	)		919,497
Nonvested RSUs as of December 31, 2025		20,000			118,400

Share-Based Payment Arrangement, Activity [Table Text Block]

	Number of Shares			Weighted-Average Exercise Price
Outstanding as of December 31, 2024		3,101		$	1,240.50
Issued		-			-
Expired		(176	)		20,729.18
Exercised		-			-
Outstanding as of December 31, 2025		2,925		$	1,334.07

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Range of Exercise Prices		Shares		Weighted Average Remaining Life
$	93.30 –121.80		64		7.02
$	219.75 –375.00		819		4.97
$	393.00 –492.00		896		2.97
$	783.00 –12,750.00		1,146		2.68
Total			2,925

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

Year	Shares		Range of Exercise Prices
2016		25		462.00	–		12,750.00
2017		678		462.00	–		6,300.00
2018		205		462.00	–		3,390.00
2019		903		462.00	–		2,370.00
2020		1,002		219.75	–		492.00
2021		48		375.00	–		399.00
2022		48		115.50	–		219.75
2023		16		93.30	–		93.30
2024		-		-	–		-
2025		-		-	–		-
Total		2,925	$	93.30	–	$	17,250.00

Note 9 - Contingencies

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Text Block]

NOTE 9 – CONTINGENCIES

In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes, or claims. In accordance with FASB ASC Topic 450, Contingencies (“ASC 450”), the Company accrues a liability for legal contingencies when it is probable that a liability has been incurred, and the amount of the loss can be reasonably estimated. If there is at least a reasonable possibility that a loss may be incurred, ASC 450 requires disclosure of a loss contingency.

On January 1, 2025, the Company entered into a binding letter of intent (the “LOI”) with Lunai Bioworks (formerly Renovaro, Inc.) (NASDAQ: LNAI, formerly RENB) (“Renovaro”) for Axe Compute to be acquired by Renovaro (the “Renovaro Merger”). Under the terms of the LOI, Axe Compute would be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. On February 28, 2025, Axe Compute entered into an extension agreement with Renovaro (the “Extension Agreement”), pursuant to which the parties amended certain terms of the LOI, including to extend the outside termination date of the LOI from February 28, 2025 to March 31, 2025. No definitive purchase agreement was executed as of March 31, 2025 and the LOI terminated on that date, pursuant to its terms. Axe Compute had no further obligations with respect to the Renovaro Merger, including under the LOI or the Extension Agreement. On April 3, 2025, Axe Compute’s Board of Directors notified Renovaro of the Company’s decision to discontinue discussions regarding the proposed merger between the two companies.

On May 8, 2025, Renovaro filed a lawsuit in Delaware Chancery Court claiming breaches by the Company of the LOI and the Extension Agreement and seeking to compel the Company to enter into a merger agreement with Renovaro. The Company does not believe the lawsuit has merit and continues to contest it vigorously. It is not possible to estimate the amount of any loss or range of possible loss that might result from this lawsuit. However, because the final outcome cannot be predicted with certainty, unfavorable or unexpected developments or outcomes could result in a material impact to the Company’s financial condition and results of operations.

Note 14 - Income Taxes - Schedule of Income Taxes Paid (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
U.S. Federal	$ 0	$ 0
U.S. State	0	0
Foreign	0	0
Total income taxes paid (net of refunds)	$ 0	$ 0

Note 14 - Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Text Block]

NOTE 14 – INCOME TAXES

Income taxes paid, net of refunds, disaggregated by jurisdiction are as follows:

	Year Ended December 31,
	2025		2024
U.S. Federal	$	-	$	-
U.S. State		-		-
Foreign		-		-
Total income taxes paid (net of refunds)	$	-	$	-

Pretax income is entirely related to domestic activities. The Company did not have any foreign operations.

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The Company incurred zero income tax expense from continuing operations during the years ended December 31, 2025, and 2024, due to losses in both years.

Actual income tax benefit from continuing operations differs from statutory federal income tax expense (benefit) as follows*:

	Year Ended December 31,
	2025					2024
Tax computed at the statutory federal rate	$	(48,929,078	)	21.00	%		2,147,178		19.77	%
State income taxes, net of federal benefit (a)		-		0.00	%	$	-		0.00	%
Nontaxable or nondeductible items
Fair value of embedded derivatives		10,287,060		-4.42	%		-		0.00	%
Fair value of equity warrants		3,265,308		-1.40	%		-		0.00	%
Other nontaxable or nondeductible items		9,309		0.00	%		9,183		0.08	%
Other		124,835		-0.05	%		(13,898	)	-0.13	%
Change in valuation allowance		35,242,566		-15.13	%		(2,142,462	)	-19.73	%
Taxes at effective rate	$	-		0.00	%	$	-		0.00	%

*Certain prior-period amounts have been recast to reflect the classification of the Company's Eagan business as discontinued operations in 2025. Accordingly, amounts presented, including the effective tax rate reconciliation, reflect continuing operations only.

Deferred taxes consist of the following:

	December 31, 2025			December 31, 2024
Deferred tax assets:
Compensation accruals	$	99,684		$	42,893
Accruals and reserves		172,188			191,804
Deferred revenue		35,819			80,005
Charitable contribution carryover		1,717			1,742
Unrealized loss on digital assets		39,397,315			-
Intangibles		591,011			696,622
Capitalized R&D		711,632			1,016,330
Lease liabilities		387,395			551,917
Stock-based compensation		570,708			542,609
NOL and credits		27,010,332			24,479,583
Total deferred tax assets		68,977,801			27,603,505

Deferred tax liabilities:
Depreciation		(45,520	)		(31,863	)
Lease right-of-use assets		(369,859	)		(513,256	)
Total deferred tax liabilities		(415,379	)		(545,119	)

Net deferred tax assets		68,562,422			27,058,386
Less: valuation allowance		(68,562,422	)		(27,058,386	)
Total	$	-		$	-

The Company evaluates the realizability of deferred tax assets and considers all available evidence, both positive and negative, including historical operating results, projections of future taxable income, reversing taxable temporary differences, and tax planning strategies. The Company has determined based on available evidence, particularly its history of losses, that it is not more likely than not that its net deferred tax asset will be realizable. Accordingly, the Company maintains a full valuation allowance against its net deferred tax asset.

Pursuant to the Internal Revenue Code of 1986, as amended (the “Code”) Sections 382 and 383, annual use of a company’s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.

As of December 31, 2025, the Company had $110,759,174 of NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2026, subject to the Section 382 limitations described above. The federal NOLs of $14,857 begin to expire in 2026 if unused and $110,744,317 will carry forward indefinitely. The Company also had $57,161,699 of NOLs to reduce future state taxable income as of December 31, 2025. The state NOLs will begin to expire in 2026 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. As of December 31, 2025, the federal and state valuation allowances were $55,645,772 and $12,916,650, respectively.

During the year-ended December 31, 2023, the Company completed an assessment of the available NOL and tax credit carryforwards under Section 382 and 383 and determined that the Company underwent several ownership changes during the period from 2008 to 2022. The Company adjusted its NOL and tax credit carryforwards to reflect the limitations resulting from the identified ownership changes. The Company reduced its available gross federal and state NOL carryforwards and the federal and state deferred tax asset, each of which related to losses generated for the years ended December 31, 2022, and prior.

During the year-ended December 31, 2025, the Company underwent a Section 382 analysis for the periods presented in the consolidated financial statements and determined that the Company experienced an ownership change (as defined in Section 382) related to its Cash PIPE equity issuance on October 7, 2025. The Company has calculated a preliminary Section 382 base limitation of approximately $435,000 with an aggregate limitation of approximately $4,600,000 over the applicable five-year recognition period after consideration of deemed realized built in gains (RBIG).

Tax years after 2005 remain open to examination by federal and state tax authorities due to unexpired NOL carryforwards.

The Company recognizes interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. As of December 31, 2025, and 2024, the Company recorded no accrued interest or penalties related to uncertain tax positions.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 10 - Note Payable

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Text Block]

NOTE 10 – NOTE PAYABLE

In June 2025, the Company purchased director and officer insurance policies with a policy period ending June 2026 and financed $264,048 of its total premium by entering into a note payable with a finance provider that requires ten monthly installment payments through April 2026. The note is secured by a first priority lien on the financed policies. The short-term note bears interest at an annual percentage rate of 6.6% over the life of the note. As of December 31, 2025, the outstanding balance of the note was $107,951 including interest.

In June 2024, the Company purchased director and officer insurance policies with a policy period ending June 2025 and financed $275,098 of its total premium by entering into a note payable with a finance provider that required ten monthly installment payments through April 2025. The note was secured by a first priority lien on the financed policies. The short-term note bore interest at an annual percentage rate of 8.0% over the life of the note. As of December 31, 2024, there was no outstanding balance on the note.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Note 11 - Stockholders' Equity - Schedule of Warrants (Details)	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Outstanding, shares (in shares)	1,623,179
Stock Warrants [Member]
Outstanding, shares (in shares)	183,411
Outstanding, average exercise price (in dollars per share) \| $ / shares	$ 133.8
Issued, shares (in shares)	1,568,939
Issued, average exercise price (in dollars per share) \| $ / shares	$ 11.64
Expired (in shares)	(29,112)
Expired, average exercise price (in dollars per share) \| $ / shares	$ 447.36
Exercised, shares (in shares)	(100,059)
Exercised, average exercise price (in dollars per share) \| $ / shares	$ 16.05
Outstanding, shares (in shares)	1,623,179
Outstanding, average exercise price (in dollars per share) \| $ / shares	$ 17.39

Note 5 - Digital Assets

12 Months Ended

Dec. 31, 2025

Crypto Asset [Text Block]

NOTE 5 – DIGITAL ASSETS

The Company’s digital assets, as shown on the consolidated balance sheet as of December 31, 2025, were primarily comprised of ATH. The following table sets forth the units held, cost basis, and fair value of ATH held as of December 31, 2025:

		Units Held				Cost Basis				Fair Value
ATH			2,837,163,868			$	101,258,178			$	24,439,334

Cost basis is equal to the cost (purchase price) of the digital assets, including transaction fees, if any, at the time of purchase or upon receipt. Fair value represents the quoted digital asset prices within the Company’s principal market at the measurement time (11:59 EST).

The following table represents a reconciliation of digital assets held, for ATH specific activity:

	For the Year Ended December 31, 2025
Fair Value, January 1, 2025	$	-
Unlocked ATH received from investors		62,973,982
ATH contributed by DCI pursuant to Side Letter		2,230,949
ATH claimed from digital asset receivable		3,445,865
Purchases of ATH		32,607,382
Disposals		-
Unrealized gain / (loss)		(76,818,844	)
Fair Value, December 31, 2025	$	24,439,334

Side Letter

In connection with the private placements completed in October 2025 to support the Treasury Strategy, the Company entered into a side letter agreement (the “Side Letter”) with DCI, effective as of October 7, 2025. The Side Letter provides, in addition to other rights afforded to the Company, that for each ATH token purchased by the Company on the open market, whether through a centralized exchange or a decentralized exchange operating on the Ethereum Network, DCI will grant to the Company an additional number of ATH tokens equal to 20% of the number of ATH tokens purchased on the open market to be delivered within 30 days of the open market purchase (the “Bonus ATH”). There are no restrictions on the Company’s use of the Bonus ATH once received. The Company accounts for the Side Letter as a derivative instrument. As of December 31, 2025, no derivative asset was recorded because the Company had received from DCI all Bonus ATH due under the Side Letter for open market purchases made during the period.

During the year ended December 31, 2025, the Company received approximately 236 million ATH with a cost basis of $2.2 million pursuant to the Side Letter as a result of open market purchases totaling approximately 1.18 billion ATH. The cost basis of the ATH received pursuant to the Side Letter and subsequent fair value adjustments thereto are recorded within “Gains (losses) on digital assets” on the Consolidated Statements of Net Loss.

Digital asset receivable

A portion of the Company’s ATH holdings consists of contractual rights to receive ATH tokens that are subject to time-based vesting and transfer restrictions (“Locked ATH”). Locked ATH was obtained pursuant to Simple Agreements for Future Tokens (“SAFTs”) and is administered through an on-chain smart contract deployed on the Ethereum mainnet. Prior to vesting and claim, the Company does not have control of the underlying ATH tokens and is not able to transfer, sell, stake, pledge, or otherwise deploy such tokens.

The smart contract enforces the applicable vesting schedules and restricts access to the ATH tokens until the vesting conditions are satisfied. Upon satisfaction of the vesting conditions, the Company must affirmatively claim the unlocked ATH tokens through the smart contract interface, at which point the tokens are released from restriction and transferred to a Company-controlled wallet. Until such claim occurs, the Locked ATH represents a contractual right to receive ATH in the future rather than a digital asset held by the Company.

As of December 31, 2025, the Company held rights to receive ATH tokens that remain subject to vesting and claim requirements. The vesting period for these ATH tokens ranges from less than one month to approximately 3 years. These restrictions are specific to the underlying ATH tokens. Upon vesting and claim, the restrictions lapse and the Company obtains control of the ATH tokens, which may then be held, transferred to custodial accounts, staked, or otherwise deployed in accordance with the Company’s Treasury Strategy.

As of December 31, 2025, the Company had a digital asset receivable $15.5 million related to the Locked ATH comprised of the host receivable recorded at $93.4 million, net of the embedded derivative measured at fair value of $77.9 million. The change in fair value of the embedded derivative of $77.9 million during the year ended December 31, 2025 is recorded in the consolidated statements of net loss within “Gains (losses) on digital assets.”

Note 3 - Discontinued Operations

12 Months Ended

Dec. 31, 2025

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

NOTE 3 – DISCONTINUED OPERATIONS

In July 2024, the Company’s Board of Directors approved a plan to implement a strategic cost savings initiative, primarily related to the Company’s Birmingham laboratory. In September 2024, the Company transferred certain pieces of computer hardware with alternative use to the Pittsburgh laboratory, which conducts the Company’s oncology drug discovery business, while the rest of the laboratory equipment and inventories from the Birmingham laboratory were marketed for sale and the related product and service lines were discontinued. The Company executed a sales agreement for all remaining laboratory equipment and inventories from the Birmingham laboratory and all items were removed from the laboratory premises as of September 30, 2024. As of September 30, 2024, the Company vacated and ceased use of the Birmingham laboratory and office space. The Company’s lease continued through August 2025. The Company concluded that, in aggregate, the disposal of the assets comprising the former Birmingham operating segment met the criteria for discontinued operations presentation in the third quarter of 2024.

On March 14, 2025, the Company entered into an asset purchase agreement (the “APA”) and closed the transactions contemplated therein with DeRoyal Industries, Inc., a Tennessee corporation (“DeRoyal”), to sell and assign to DeRoyal assets and liabilities exclusively related to the business of providing products for automated, direct-to-drain medical fluid disposal, including the Company’s STREAMWAY® product line (the “Eagan Business”). These assets were operated by the Company’s wholly owned subsidiary, Skyline Medical, and were previously reported in the Company’s Eagan operating segment. The purchased assets exclusively related to the Eagan Business included but were not limited to cash, certain accounts receivable, inventories, patents, fixed assets, and real property leased by the Company and exclusively used in connection with the Eagan Business. The total purchase price for the purchased assets was $625,000, plus the assumption of certain liabilities related to the Eagan Business including the lease for the office and warehouse space located at 2915 Commers Drive Suite 900 Eagan, MN 55121, certain accounts payable, and contract liabilities associated with the Eagan Business.

As a result of these developments, the former Birmingham and Eagan operating segments have been reclassified to discontinued operations in these condensed consolidated financial statements for all periods presented.

The following table presents a reconciliation of the carrying amounts of the major classes of assets and liabilities to the current assets and liabilities of discontinued operations as presented in the Company’s condensed consolidated balance sheets:

	December 31, 2025		December 31, 2024
Assets:
Cash	$	-	$	122,851
Accounts receivable, net		-		746,266
Inventories		-		339,968
Prepaid expense and other assets		-		52,318
Total current assets of discontinued operations		-		1,261,403

Property and equipment, net		-		21,882
Intangibles, net		-		159,158
Lease right-of-use assets		-		17,266
Other long-term assets		-		4,031
Total assets of discontinued operations	$	-	$	1,463,740

Liabilities:
Accounts payable	$	-	$	97,780
Accrued expenses and other liabilities		-		248,086
Contract liabilities		-		80,909
Lease liability		-		106,609
Total current liabilities of discontinued operations		-		533,384

Lease liability – net of current portion		-		-
Other long-term liabilities		-		23,487
Total liabilities	$	-	$	556,871

The following table provides details about the major classes of line items constituting the loss from discontinued operations presented in the Company’s consolidated statements of net loss:

	Year Ended December 31,
	2025			2024
Revenue	$	157,179		$	1,571,795
Cost of sales		122,800			751,147
Gross profit from discontinued operations		34,379			820,648

Operating expenses:
General and administrative		209,550			1,039,950
Operations, research and development		126,505			1,115,595
Sales and marketing		130,318			637,400
Total operating expenses		466,373			2,792,945
Total operating (loss) from discontinued operations		(431,994	)		(1,972,297	)
Gain (loss) on disposal of discontinued operations		172,451			(463,127	)
Other income (expense)		17,987			(4,309	)
Net (loss) from discontinued operations	$	(241,556	)	$	(2,439,733	)

The gain on disposal of discontinued operations for the year ended December 31, 2025 represents the gain on assets sold and liabilities assumed by DeRoyal related to the former Eagan operating segment. The loss on disposal of discontinued operations for the year ended December 31, 2024 represents the loss on impairment of assets sold, including laboratory equipment and inventories, and impairment of other non-current assets related to the former Birmingham operating segment.

Note 11 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Number of Shares			Weighted-Average Exercise Price
Outstanding as of December 31, 2024		183,411		$	133.80
Issued		1,568,939			11.64
Expired		(29,112	)		447.36
Exercised		(100,059	)		16.05
Outstanding as of December 31, 2025		1,623,179		$	17.39

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Year Ended December 31,
	2025			2024
Expected dividend yield		0.0	%		0.0	%
Expected stock price volatility		99.4% - 103.5	%		97.3	%
Risk-free interest rate		3.71% - 4.37	%		4.06% –4.58	%
Expected life (in years)		5			1.5 –5

Schedule of Share-based Compensation Shares Authorized Under Warrant Plans by Exercise Price Range [Table Text Block]

Range of Exercise Prices		Shares		Weighted Average Remaining Life
$	11.63 –16.05		1,594,935		4.72
$	24.75 –28.13		6,171		3.73
$	210.00 –240.00		8,221		1.39
$	300.00 –731.25		13,852		0.51
Total			1,623,179

Disclosure of Warrant Information [Table Text Block]

Year	Shares		Range of Exercise Prices
2021		15,733		240.00	–		731.25
2022		6,340		210.00	–		225.00
2023		-		-	–		-
2024		32,167		16.05	–		24.75
2025		1,568,939		11.63	–		28.13
Total		1,623,179	$	11.63	–	$	731.25

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2025	Dec. 31, 2024
Preferred Stock, Shares Authorized (in shares)	20,000,000	20,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Common Stock, Shares Authorized (in shares)	200,000,000	200,000,000
Common Stock, Shares, Outstanding (in shares)	4,083,173	444,475
Common Stock, Shares, Issued (in shares)	4,083,173	444,475
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)	2,300,000	2,300,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding (in shares)	79,246	79,246

Note 17 - Segment Information

12 Months Ended

Dec. 31, 2025

Segment Reporting Disclosure [Text Block]

NOTE 17 – SEGMENT INFORMATION

The Company has determined its operating segments in accordance with ASC 280, Segment Reporting. Factors used to determine the Company’s reportable segments include the availability of separate financial statements, the existence of separate leadership across business lines, the economic factors affecting each segment, and the evaluation of operating results at the segment level. The Company’s Chief Operating Decision Maker (“CODM”), its chief executive officer, allocates the Company’s resources for each of the operating segments and evaluates their relative performance based on gross profit, operating loss, and net loss. Operating expenses are disaggregated by department for purposes of evaluating each segment’s performance. Each operating segment listed below has separate financial statements and locally based leadership that are evaluated based on the results of their respective segments. It should be noted that the operating segments below have different products and services.

The Company has two reportable segments, which have been delineated by business area:

●

Compute Services and Treasury Management segment: provides services that include access to GPU compute capacity and manages the Company’s ATH Treasury Strategy.

●

Drug Discovery Services segment: provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples, as well as creation of proprietary 3D culture models used in drug development.

As described in Note 3 – Discontinued Operations, the Company’s former Birmingham and Eagan operating segments met the criteria to be reported as discontinued operations during the third quarter of 2024 and first quarter of 2025, respectively. As such, the former Birmingham and Eagan operating segments are excluded from the tables below, which only reflect continuing operations for all periods presented.

See discussion of revenue recognition in Note 2 – Summary of Significant Accounting Policies for a description of the products and services recognized in each segment. All revenues are earned from external customers.

The tables below summarize the Company’s segment reporting as of and for the years ended December 31, 2025, and 2024.

	Year Ended December 31, 2025
	Compute Services and Treasury Management			Drug Discovery Services			Corporate			Total
Revenue	$	-		$	125,284		$	-		$	125,284
Gains and (losses) from operations		(152,490,550	)		-			-			(152,490,550	)
Cost of revenues		-			72,622			-			72,622
General and administrative expenses		16,241,611			1,726,908			7,955,839			25,924,358
Research and development expenses		-			2,137,042			10,180			2,147,222
Sales and marketing expenses		-			-			406,247			406,247
Total operating (loss)		(168,732,161	)		(3,811,288	)		(8,372,266	)		(180,915,715	)
Gain (loss) on derivative instruments		(52,735,000	)		-			-			(52,735,000	)
Other segment items		117,463			676,702			2,903			797,068
Segment loss	$	(221,349,698	)	$	(3,134,586	)	$	(8,369,363	)	$	(232,853,647	)

	December 31, 2025
	Compute Services and Treasury Management		Drug Discovery Services		Corporate		Total
Assets	$	49,455,174	$	1,930,898	$	1,502,274	$	52,888,346
Depreciation and amortization		-		121,261		7,777		129,038
Expenditures for additions to long-lived assets		-		-		-		-

	Year Ended December 31, 2024
	Compute Services and Treasury Management		Drug Discovery Services			Corporate			Total
Revenue	$	-	$	84,812		$	-		$	84,812
Cost of revenues		-		78,285			-			78,285
General and administrative expenses		-		2,022,732			5,213,065			7,235,797
Research and development expenses		-		2,234,501			6,960			2,241,461
Sales and marketing expenses		-		5			833,194			833,199
Total operating loss		-		(4,250,711	)		(6,053,219	)		(10,303,930	)
Other segment items		-		(606	)		79,881			79,275
Segment loss	$	-		(4,251,317	)	$	(5,973,338	)	$	(10,224,655	)

	December 31, 2024
	Compute Services and Treasury Management		Drug Discovery Services		Corporate		Total
Assets	$	-	$	2,615,291	$	893,487	$	3,508,778
Depreciation and amortization		-		124,939		7,397		132,336
Expenditures for additions to long-lived assets		-		3,032		-		3,032

Other segment items is comprised of other income and other expenses. Other income primarily consists of aged accounts payable and accrued expenses written off in the year ended December 31, 2025, and interest income in the year ended December 31, 2024. Other expenses primarily consist of interest expense.

In each of the years ended December 31, 2025, and 2024, substantially all the Company revenues were located or derived from operations in the United States. As of December 31, 2025, all the Company’s long-lived assets were located within the United States.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Note 8 - Leases (Details Textual) - USD ($)	12 Months Ended
Note 8 - Leases (Details Textual) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Operating Lease, Expense	$ 784,674	$ 784,873

Note 3 - Discontinued Operations - Schedule of Disposal Groups by Balance Sheet Classification (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024
Total current assets of discontinued operations	$ 0	$ 1,261,403
Total assets of discontinued operations	0	202,337
Total current liabilities of discontinued operations	0	533,384
Discontinued Operations, Disposed of by Sale [Member] \| Birmingham Laboratory and Eagan Business [Member]
Cash	0	122,851
Accounts receivable, net	0	746,266
Inventories	0	339,968
Prepaid expense and other assets	0	52,318
Total current assets of discontinued operations	0	1,261,403
Property and equipment, net	0	21,882
Intangibles, net	0	159,158
Lease right-of-use assets	0	17,266
Other long-term assets	0	4,031
Total assets of discontinued operations	0	1,463,740
Accounts payable	0	97,780
Accrued expenses and other liabilities	0	248,086
Contract liabilities	0	80,909
Lease liability	0	106,609
Total current liabilities of discontinued operations	0	533,384
Lease liability – net of current portion	0	0
Other long-term liabilities	0	23,487
Total liabilities	$ 0	$ 556,871

Note 8 - Leases

12 Months Ended

Dec. 31, 2025